[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1179
1. Gualco G, Weiss LM, Bacchi CE: Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. Hum Pathol; 2008 Oct;39(10):1505-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma.
  • Immunohistochemical determination of p63 protein is frequently used in the pathologic diagnosis of nonhematological solid tumors.
  • In malignant hematological disease, p63 expression has been reported in 22% of follicular lymphoma, about 35% of diffuse large B-cell lymphoma, 23% of chronic lymphocytic leukemia, and in some cases of blast crisis of chronic myelogenous leukemia.
  • Anaplastic large cell lymphoma is a rare disease that accounts for less than 5% of all cases of non-Hodgkin's lymphoma.
  • There is little information concerning p63 expression in this specific type of lymphoma.
  • In some cases, the morphological and phenotypic features between anaplastic large cell lymphoma and classical Hodgkin's lymphoma are similar, making this differential diagnosis challenging.
  • We studied p63 expression using a tissue microarray approach in 154 cases of anaplastic large cell lymphoma, including 38% anaplastic large cell kinase positive and 62% anaplastic large cell kinase negative, and 58 Hodgkin's lymphoma cases.
  • Sixty-eight cases of anaplastic large cell lymphoma (44%) showed p63 nuclear positivity (41% of anaplastic large cell kinase positive and 47% of anaplastic large cell kinase negative).
  • Of 130 cases of systemic-anaplastic large cell lymphoma, 42% showed p63 positivity.
  • The neoplastic cells expressed p63 in 38% of the cases of CD45-negative/anaplastic large cell kinase-negative null cell-type anaplastic large cell lymphoma, a subgroup that offers the most difficulties in the differential diagnosis with classical Hodgkin's lymphoma.
  • In contrast, none of the cases of classical Hodgkin's lymphoma demonstrated any p63 expression.
  • These results demonstrate that p63 protein expression is frequently expressed in a subset of anaplastic large cell lymphoma cases and may be used as a potential tool in the differential diagnosis between anaplastic large cell lymphoma and classical Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):709-17 [15151211.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1199-206 [12368193.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1221-6 [12429802.001]
  • [Cites] J Pathol. 2002 Dec;198(4):417-27 [12434410.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):199-204 [12579989.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):223-9 [16434897.001]
  • [Cites] Haematologica. 2006 May;91(5):596-604 [16670065.001]
  • [Cites] Urology. 2004 Jun;63(6):1079-83 [15183954.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] Pathol Biol (Paris). 1997 Dec;45(10):898-908 [9769955.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3352-6 [10416592.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):237-42 [16082248.001]
  • [Cites] J Korean Med Sci. 2005 Oct;20(5):752-8 [16224147.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):233-9 [17297297.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1062-71 [17426453.001]
  • [Cites] Arch Pathol Lab Med. 2007 May;131(5):742-7 [17488159.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):709-14 [16837628.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1127-38 [17577776.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7113-21 [14612504.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • (PMID = 18620733.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS127050; NLM/ PMC2744879
  •  go-up   go-down


2. Matsushita H, Nakamura N, Asai S, Yabe M, Hayama N, Kondo Y, Urano T, Miyachi H: A leukemic change as an initial manifestation of the common variant type of ALK-positive anaplastic large cell lymphoma in a patient with lung adenocarcinoma. Intern Med; 2008;47(23):2057-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A leukemic change as an initial manifestation of the common variant type of ALK-positive anaplastic large cell lymphoma in a patient with lung adenocarcinoma.
  • We report an 81-year-old man who had leukemic presentation of ALK-positive anaplastic large cell lymphoma (ALCL) as an initial manifestation.
  • The peripheral blood smear and bone marrow aspiration revealed the infiltration of atypical large cells with horseshoe-shaped or lobulated nuclei.
  • The detection of CD30 expression and the t (2;5) (p23;q35) translocation in these cells was confirmatory of a diagnosis of common variant ALK-positive ALCL in a leukemic phase.
  • An adequate, prompt diagnosis is necessary for this rare disease status in oncologic emergency to improve the disease management.
  • [MeSH-major] Adenocarcinoma / diagnosis. Genetic Variation / genetics. Lung Neoplasms / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antigens, CD30 / genetics. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043261.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Number-of-references] 20
  •  go-up   go-down


3. Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM: Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature. Haematologica; 2006 Dec;91(12 Suppl):ECR55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature.
  • An autopsy of the pancreas revealed clusters of large, atypical cells, which morphologically and immunophenotypically were consistent with CD30 positive, ALK-negative anaplastic large cell lymphoma (ALCL) of T-cell lineage and multifocal fat necrosis (panniculitis) in the peripancreatic adipose tissue.
  • This is the first case of ALCL of the pancreas and panniculitis in a patient with history of AML.
  • [MeSH-major] Leukemia, Myeloid / drug therapy. Lymphoma, Large-Cell, Anaplastic / diagnosis. Neoplasms, Second Primary / diagnosis. Pancreas / pathology. Panniculitis / etiology
  • [MeSH-minor] Acute Disease. Aged. Fatal Outcome. Humans. Male. Neoplasm Proteins / analysis. Respiratory Insufficiency / etiology


Advertisement
4. Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella-Deana A, Marin O, Perrotti D, Gambacorti-Passerini C: NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood; 2007 Oct 1;110(7):2600-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
  • The oncogenic fusion tyrosine kinase nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) induces cellular transformation in anaplastic large-cell lymphomas (ALCLs) carrying the t(2;5) chromosomal translocation.
  • The interaction between NPM/ALK and PSF was dependent on an active ALK kinase domain and PSF was found to be tyrosine-phosphorylated in NPM/ALK-expressing cell lines and in primary ALK(+) ALCL samples.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Oct 24;272(43):27369-77 [9341188.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2901-10 [9376569.001]
  • [Cites] Oncogene. 1997 Oct;15(18):2233-9 [9393982.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4442-55 [9687511.001]
  • [Cites] RNA. 1998 Aug;4(8):998-1006 [9701290.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26261-4 [9756848.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6951-61 [9819383.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):455-66 [9914158.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):163-8 [9923858.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):761-72 [10036227.001]
  • [Cites] J Cell Biol. 1999 May 3;145(3):447-55 [10225947.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5205-10 [15590677.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1183-97 [15772089.001]
  • [Cites] Nat Med. 2005 Jun;11(6):623-9 [15895073.001]
  • [Cites] Biochemistry. 2005 Jun 14;44(23):8533-42 [15938644.001]
  • [Cites] Expert Opin Ther Targets. 2005 Jun;9(3):515-32 [15948671.001]
  • [Cites] Haematologica. 2005 Jul;90(7):988-90 [15996942.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3191-6 [16101126.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2194-9 [11280786.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:779-808 [9442887.001]
  • [Cites] Exp Cell Res. 2001 Feb 1;263(1):131-44 [11161712.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2298-311 [11259580.001]
  • [Cites] Br J Haematol. 2001 May;113(2):275-95 [11380391.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6517-23 [11522649.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1559-66 [11888936.001]
  • [Cites] J Cell Biochem. 2002;86(2):394-402 [12112008.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):915-27 [12196509.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Oct;283(4):E794-8 [12217897.001]
  • [Cites] RNA. 2002 Sep;8(9):1102-11 [12358429.001]
  • [Cites] RNA. 2002 Oct;8(10):1334-47 [12403470.001]
  • [Cites] FEBS Lett. 2002 Nov 6;531(2):109-14 [12417296.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12189-93 [16079199.001]
  • [Cites] Nature. 2005 Sep 1;437(7055):147-53 [16007073.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1391-8 [16273072.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):355-68 [16286244.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3907-16 [16105984.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2780-8 [16835382.001]
  • [Cites] Biochem Cell Biol. 1999;77(4):293-8 [10546892.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] J Cell Biochem. 2000 Jan;76(4):559-66 [10653975.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2144-9 [10706887.001]
  • [Cites] Blood. 2000 May 15;95(10):3204-7 [10807789.001]
  • [Cites] Mol Endocrinol. 2000 Jun;14(6):774-82 [10847580.001]
  • [Cites] Anal Chem. 2000 Jun 1;72(11):2482-9 [10857624.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6159-69 [10913197.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 15;28(16):3022-30 [10931916.001]
  • [Cites] Cell. 2000 Sep 29;103(1):127-40 [11051553.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] Eur J Biochem. 2001 Jan;268(2):420-8 [11168378.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Exp Hematol. 2003 Apr;31(4):309-15 [12691918.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4642-7 [12879008.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):30028-36 [12748172.001]
  • [Cites] Oncogene. 2003 Aug 7;22(32):5031-44 [12902986.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6618-30 [12944487.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2617-29 [14968112.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41727-33 [15292236.001]
  • [Cites] Cell. 1989 Feb 10;56(3):379-90 [2914325.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2615-26 [2527334.001]
  • [Cites] J Biol Chem. 1989 Sep 5;264(25):15006-11 [2768249.001]
  • [Cites] Biochemistry. 1989 Nov 28;28(24):9495-501 [2482073.001]
  • [Cites] Cell. 1992 May 1;69(3):539-49 [1581965.001]
  • [Cites] Genes Dev. 1993 Mar;7(3):393-406 [8449401.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3598-610 [7684501.001]
  • [Cites] Nat Genet. 1993 Jun;4(2):175-80 [7503811.001]
  • [Cites] Nucleic Acids Res. 1993 Aug 25;21(17):4085-92 [8371983.001]
  • [Cites] Protein Eng. 1993 Aug;6(6):557-64 [8234226.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1567-74 [8183550.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14):3356-67 [8045264.001]
  • [Cites] Oncogene. 1994 Oct;9(10):3087-97 [8084618.001]
  • [Cites] J Biol Chem. 1995 Aug 11;270(32):18715-8 [7642516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6 [8633037.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1828-39 [9292515.001]
  • (PMID = 17537995.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA092318; United States / NCI NIH HHS / CA / R01 CA095512; United States / NCI NIH HHS / CA / CA095512; United States / NCI NIH HHS / CA / CA92318
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / PTB-associated splicing factor; 0 / RNA-Binding Proteins; 21820-51-9 / Phosphotyrosine; 63231-63-0 / RNA; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC1988934
  •  go-up   go-down


5. Hernandez C, Puangsuvan SN, Peterson A, Robinson JK: Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma. Clin Exp Dermatol; 2009 Dec;34(8):e722-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma.
  • We report an unusual case of localized cutaneous nodules heralding the recurrence of systemic CD30+ anaplastic large-cell lymphoma (ALCL).
  • A 47-year-old woman developed numerous violaceous nodules in the perineal and upper thigh area 3 years after multimodal treatment and complete remission of primary anaplastic large-cell CD30+ lymphoma.
  • Using immunohistochemical and T-cell gene rearrangement analysis, a recurrence of her anaplastic large-cell lymphoma was diagnosed.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD30 / genetics. Cell Transformation, Neoplastic / genetics. Female. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Middle Aged. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055841.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


6. Lagmay J, Termuhlen A, Fung B, Ranalli M: Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient. J Pediatr Hematol Oncol; 2009 May;31(5):330-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient.
  • Anaplastic large cell lymphoma is a heterogeneous group of malignant non-Hodgkin lymphomas that occurs in up to 15% of all pediatric non-Hodgkin lymphomas.
  • This brief report describes first reported case of pediatric primary testicular anaplastic large cell lymphoma in a 14-year-old boy.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / metabolism. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antigens, CD30 / metabolism. Biomarkers, Tumor / metabolism. Biopsy. Cell Nucleus / metabolism. Cell Nucleus / pathology. Golgi Apparatus / metabolism. Golgi Apparatus / pathology. Humans. Male. Orchiectomy. Testis / pathology. Testis / surgery

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415011.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


7. Cho SG, Koh YB, Chang HS, Park G, Kang CS, Park JW, Min WS: Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation. Eur J Haematol; 2005 Mar;74(3):259-62
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation.
  • A 25-yr-old man had been diagnosed as having CD30(+) anaplastic large cell lymphoma associated with hemophagocytic syndrome (HS).
  • He received aggressive frontline chemotherapies and consolidation with autologous peripheral blood stem cell transplantation (PBSCT) following high-dose chemotherapy combined with splenic irradiation (720 cGy in fraction of 180 cGy).
  • However, HS recurred on day 50 of PBSCT without radiologic evidence of lymphoma relapse.
  • HS was completely resolved and he has been alive well and in complete remission (CR), 60 months after initial diagnosis.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / therapy. Interferon-alpha / therapeutic use. Lymphoma, Large-Cell, Anaplastic / complications. Splenectomy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Humans. Male. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction / methods

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693797.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


8. Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R: Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem; 2010 Aug 20;285(34):26441-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
  • Most anaplastic large cell lymphomas (ALCL) express oncogenic fusion proteins derived from chromosomal translocations or inversions of the anaplastic lymphoma kinase (ALK) gene.
  • Frequently ALCL carry the t(2;5) translocation, which fuses the ALK gene to the nucleophosmin (NPM1) gene.
  • The transforming activity mediated by NPM-ALK fusion induces different pathways that control proliferation and survival of lymphoma cells.
  • Grb2 is an adaptor protein thought to play an important role in ALK-mediated transformation, but its interaction with NPM-ALK, as well as its function in regulating ALCL signaling pathways and cell growth, has never been elucidated.
  • Furthermore, Grb2 did not bind to a single region but rather to different regions of NPM-ALK, mainly Tyr(152-156), Tyr(567), and a proline-rich region, Pro(415-417).
  • Finally, shRNA knockdown experiments showed that Grb2 regulates primarily the NPM-ALK-mediated phosphorylation of SHP2 and plays a key role in ALCL cell growth.
  • [MeSH-major] Cell Proliferation. GRB2 Adaptor Protein / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Oncogene Proteins, Fusion / metabolism. Protein-Tyrosine Kinases / metabolism. Signal Transduction
  • [MeSH-minor] Binding Sites. Humans. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Phosphorylation. Protein Binding. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Receptor Protein-Tyrosine Kinases. Translocation, Genetic. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):793-8 [10706082.001]
  • [Cites] Mol Cell Biol. 2009 May;29(10):2505-20 [19273609.001]
  • [Cites] J Mol Biol. 2001 Feb 23;306(3):527-37 [11178911.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6793-804 [11726515.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1438-48 [12149229.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):850-8 [12402043.001]
  • [Cites] Mol Cell Biol. 2002 Dec;22(23):8375-87 [12417738.001]
  • [Cites] Cell Signal. 2003 Mar;15(3):319-26 [12531430.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] J Virol. 2003 Aug;77(16):8957-61 [12885912.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2617-29 [14968112.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] Cell. 1992 Aug 7;70(3):431-42 [1322798.001]
  • [Cites] Nature. 1992 Dec 17;360(6405):689-92 [1465135.001]
  • [Cites] Cell. 1993 Oct 8;75(1):175-85 [8402896.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2777-85 [7511210.001]
  • [Cites] Cell. 1994 Apr 22;77(2):261-71 [7513258.001]
  • [Cites] Science. 1995 Jan 20;267(5196):316-7 [7824924.001]
  • [Cites] Science. 1995 Apr 14;268(5208):291-3 [7716522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10889-93 [7479904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6 [8633037.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13116-22 [8662733.001]
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):14119-23 [8662889.001]
  • [Cites] Crit Rev Immunol. 1996;16(3):251-75 [8922899.001]
  • [Cites] Arch Biochem Biophys. 1997 Jan 15;337(2):143-8 [9016807.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] FASEB J. 1997 Oct;11(12):965-72 [9337149.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2901-10 [9376569.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2846-51 [10077599.001]
  • [Cites] Mutat Res. 2005 Feb 15;570(1):9-15 [15680399.001]
  • [Cites] Cancer Gene Ther. 2005 May;12(5):456-63 [15719029.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3907-16 [16105984.001]
  • [Cites] Anticancer Drugs. 2006 Jan;17(1):13-20 [16317285.001]
  • [Cites] Blood. 2006 Jan 15;107(2):689-97 [16189272.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1617-23 [16254137.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4278-86 [17483340.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Cancer Sci. 2008 Mar;99(3):479-85 [18177485.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2776-90 [18845790.001]
  • [Cites] Semin Oncol. 2009 Apr;36(2 Suppl 1):S27-35 [19393833.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1165-9 [11007954.001]
  • (PMID = 20554525.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] International / European Research Council / / 242965
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GRB2 Adaptor Protein; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11
  • [Other-IDs] NLM/ PMC2924075
  •  go-up   go-down


9. Weinberg OK, Seo K, Arber DA: Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary? Hum Pathol; 2008 Sep;39(9):1331-40
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary?
  • The frequency of bone marrow involvement in anaplastic large cell lymphoma has been reported with great variation.
  • A prior study found that anaplastic large cell lymphoma involvement of bone marrow was often not evident on routine stains and advocated using immunohistochemical studies.
  • We evaluated 70 bone marrow biopsies from 41 patients with anaplastic large cell lymphoma and found 10 morphologically involved cases (14% of all biopsies, 22% of all patients).
  • In most cases (9/10 biopsies), the involvement of the bone marrow by anaplastic large cell lymphoma was massive and, thus, was evident on the hematoxylin and eosin section.
  • To determine if the hematoxylin and eosin evaluation missed bone marrow involvement, we used a panel of antibodies including CD30, ALK-1, epithelial membrane antigen, and granzyme.
  • Only the 10 morphologically involved cases showed anaplastic large cell lymphoma cells with distinct CD30 expression.
  • Other stains highlighted only a subset of the CD30-positive cases.
  • Overall, marrow involvement in anaplastic large cell lymphoma was relatively uncommon, and when present, it was identified on hematoxylin and eosin sections.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, CD30 / immunology. Child. Child, Preschool. Clone Cells / pathology. Eosine Yellowish-(YS). Female. Hematoxylin. Humans. Immunohistochemistry. Male. Middle Aged. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602674.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


10. Boudova L, Kazakov DV, Jindra P, Sima R, Vanecek T, Kuntscher V, Vera V, Bouda J, Michal M: Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. J Cutan Pathol; 2006 Aug;33(8):584-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman.
  • BACKGROUND: Cutaneous lymphomas co-expressing CD56 and CD30 are very rare.
  • They share a clinicopathological overlap with natural killer- (NK)/T-cell lymphomas and anaplastic large-cell lymphomas (ALCLs), two entities with widely disparate clinical behavior.
  • METHODS: We present a case of an immunocompetent 57-year-old Caucasian woman with a rapidly growing, angiodestructive and neuroinvasive primary cutaneous ALCL (PCALCL).
  • The neoplastic population of large anaplastic CD30+ and CD56+ T cells was masked by a massive admixture of histiocytes and neutrophils.
  • Additionally, high-dose chemotherapy with autologous peripheral blood stem-cell transplantation was administered as a consolidation of complete remission, in which she has remained for 6 years.
  • CONCLUSIONS: This is the first CD30+ and CD56+ primary skin lymphoma to be reported on the head.
  • The presented case carries a remarkable combination of clinicopathological features of PCALCL and NK-/T-cell lymphoma.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, CD56 / analysis. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Forehead. Head and Neck Neoplasms / blood supply. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / immunology. Head and Neck Neoplasms / pathology. Histiocytes / cytology. Humans. Middle Aged. Neutrophils / cytology. Scalp / blood supply. Scalp / drug effects. Scalp / innervation. Scalp / pathology. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919035.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD56
  •  go-up   go-down


11. Rust R, Blokzijl T, Harms G, Lim M, Visser L, Kamps WA, Poppema S, van den Berg A: TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells. J Pathol; 2005 Aug;206(4):445-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells.
  • Anaplastic large cell lymphomas (ALCLs) can be subdivided into two subgroups on the basis of their expression of the ALK protein.
  • ALK protein expression leads to activation of signal transducer and activator of transcription (STAT) 3, which is more commonly expressed in ALK-positive than in ALK-negative tumours.
  • In this study, we analysed TIMP-1 expression in five ALCL cell lines and 11 tumours by quantitative RT-PCR and immunohistochemistry.
  • We identified high-level TIMP-1 expression by RT-PCR in three ALK-positive ALCL-derived cell lines and in all ALK-positive ALCLs, whereas ALK-negative ALCLs generally demonstrated a lower level of TIMP-1 expression.
  • Concordant with these results, we observed TIMP-1 immunostaining in all ALK-positive ALCLs and in only two of six ALK-negative ALCLs.
  • No relationship was observed between the levels of ALK and TIMP-1 expression in the ALK-positive tumours.
  • STAT3 expression levels were similar in all ALCL samples.
  • Double staining with either CD30 or CD68 demonstrated that TIMP-1 expression was restricted to macrophages in the majority of TIMP-1-positive tumours.
  • Expression levels of IL-6 and TGF-beta1, which are cytokines known to induce TIMP-1, were higher in ALK-negative ALCLs and moderate in ALK-positive tumours.
  • Overall, no correlation was seen in ALCLs between the expression of TIMP-1 and that of cytokines that induce TIMP-1.
  • Lack of TIMP-1 expression in the tumour cells of ALK-positive ALCLs argues against a direct role for ALK-induced activation of STAT3 in the regulation of TIMP-1 expression in ALCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / chemistry. Macrophages / chemistry. Tissue Inhibitor of Metalloproteinase-1 / analysis
  • [MeSH-minor] Antigens, CD / analysis. Cell Line, Tumor. Cytokines / analysis. DNA-Binding Proteins / analysis. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry / methods. Matrix Metalloproteinases / analysis. Neoplasm Proteins / analysis. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction / methods. STAT3 Transcription Factor. Trans-Activators / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland
  • (PMID = 15920698.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Trans-Activators; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


12. Dunphy CH, DeMello DE, Gale GB: Pediatric CD56+ anaplastic large cell lymphoma: a review of the literature. Arch Pathol Lab Med; 2006 Dec;130(12):1859-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric CD56+ anaplastic large cell lymphoma: a review of the literature.
  • CONTEXT: Anaplastic large cell lymphomas (ALCLs) are a heterogeneous group of CD30+ large cell lymphomas that, according to the World Health Organization classification, are defined as being of T-cell origin, based on immunophenotype, and/or the finding of a T-cell gene rearrangement by molecular studies.
  • Relatively recent data have suggested that some T-cell ALCLs are derived from cytolytic CD4+ cells, gammadelta T cells, or natural killer-like (CD56+ or CD57+) T cells.
  • We encountered a pediatric case of CD56+, anaplastic lymphoma kinase-positive ALCL of apparent natural killer-like T-cell origin (showing positivity for CD2, cytoplasmic CD3, surface CD3 partial positivity, CD7, CD8, CD56, TIA-1, and granzyme B).
  • OBJECTIVE: To review the current pediatric literature regarding the incidence, differential diagnosis, and clinical course of such cases.
  • CONCLUSIONS: Our review did not confirm a uniformly aggressive clinical course in pediatric cases of CD56+ ALCLs.
  • Such cases suggest the usefulness of the analysis of CD56-positivity in additional cases of ALCL in an attempt to accrue additional information on this condition.
  • [MeSH-major] Antigens, CD56 / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149964.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  • [Number-of-references] 22
  •  go-up   go-down


13. Shi YF, Liu CL, Zhou CJ, Gong LP, Dong LN, Li M, Huang X, Gao ZF: [Anaplastic lymphoma kinase gene abnormality and the expression of its fusion protein in primary systemic anaplastic large cell lymphoma]. Beijing Da Xue Xue Bao; 2008 Aug 18;40(4):380-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic lymphoma kinase gene abnormality and the expression of its fusion protein in primary systemic anaplastic large cell lymphoma].
  • OBJECTIVE: To study the expression of anaplastic lymphoma kinase (ALK) and chromosome breakage of the anaplastic lymphoma kinase (ALK) gene retrospectively and to investigate their possible value as indicators of prognosis in primary systemic anaplastic large cell lymphomas (S-ALCL).
  • METHODS: Twenty-eight cases of S-ALCL were collected from the Lymphoma Lab, the Department of Pathology, Peking University Health Science Center and Beijing Children's Hospital.
  • The morphologic characteristics were studied under light microscope, and essential immunohistochemical staininings (IHC) were performed and reviewed to confirm the diagnosis of S-ALCL.
  • Locus specific interphase fluorescence in situ hybridization (LSI-FISH) was also performed on the neoplastic cells using paraffin-embedded tissues to detect ALK gene abnormality.
  • In 14 ALCL cases, ALK gene breakage was detected by LSI-FISH, using a dual-color break-apart ALK gene DNA (LSI-ALK) probe.
  • CONCLUSION: IHC detection for ALK fusion protein is important to the diagnosis of S-ALCL.
  • Complex abnormalities of ALK gene exist in S-ALCL cases, and different types of ALK gene might lead to different clinical outcome.
  • [MeSH-major] Chromosome Breakage. Lymphoma, Large-Cell, Anaplastic / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677384.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


14. Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler G: The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood; 2007 Nov 1;110(9):3374-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
  • Anaplastic large cell lymphomas (ALCLs) are highly proliferating tumors that commonly express the AP-1 transcription factor JunB.
  • ALK fusions occur in approximately 50% of ALCLs, and among these, 80% have the t(2;5) translocation with NPM-ALK expression.
  • We report greater activity of JunB in NPM-ALK-positive than in NPM-ALK-negative ALCLs.
  • Specific knockdown of JUNB mRNA using small interfering RNA and small hairpin RNA in NPM-ALK-expressing cells decreases cellular proliferation as evidenced by a reduced cell count in the G2/M phase of the cell cycle.
  • Both NPM-ALK-positive and -negative ALCL tumors demonstrate active ERK1/2 signaling.
  • In contrast to NPM-ALK-negative ALCL, the mTOR pathway is active in NPM-ALK-positive lymphomas.
  • Pharmacological inhibition of mTOR in NPM-ALK-positive cells down-regulates JunB protein levels by shifting JUNB mRNA translation from large polysomes to monosomes and ribonucleic particles (RNPs), and decreases cellular proliferation.
  • Thus, JunB is a critical target of mTOR and is translationally regulated in NPM-ALK-positive lymphomas.
  • In conjunction with NPM-ALK, JunB enhances cell cycle progression and may therefore represent a therapeutic target.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / genetics. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Protein Kinases / physiology. Protein-Tyrosine Kinases / physiology. Proto-Oncogene Proteins c-jun / genetics. Proto-Oncogene Proteins c-jun / metabolism. Transcriptional Activation


15. Rust R, Visser L, van der Leij J, Harms G, Blokzijl T, Deloulme JC, van der Vlies P, Kamps W, Kok K, Lim M, Poppema S, van den Berg A: High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma. Br J Haematol; 2005 Dec;131(5):596-608
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma.
  • Anaplastic large cell lymphomas (ALCL) are characterised by the presence of CD30-positive large cells, which usually are of T-cell type.
  • Based on the presence or absence of translocations involving the anaplastic lymphoma kinase (ALK) locus, ALCL cases can be divided into two groups.
  • To gain more insight in the biology of ALCL, we applied serial analysis of gene expression (SAGE) on the Karpas299 cell line and identified 25 up- and 19 downregulated genes.
  • Quantitative reverse transcription polymerase chain reaction on 5 ALCL cell lines and 12 ALCL tissues confirmed the SAGE data for 13 out of 14 up- and one out of four downregulated genes.
  • Immunohistochemical staining confirmed the presence of S100A10, a calcium-binding protein, in three out of five ALK+ and all 7 ALK- ALCL cases.
  • S100A11 staining was confirmed in all ALK+ and six of seven ALK- ALCL cases.
  • Three of the upregulated genes represented calcium-binding proteins, which suggest that altered intracellular signaling might be associated with the oncogenesis of ALCL.
  • [MeSH-major] Annexin A2 / genetics. Calcium Signaling / genetics. Calmodulin / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, Large B-Cell, Diffuse / genetics. S100 Proteins / genetics
  • [MeSH-minor] CD4-Positive T-Lymphocytes / metabolism. Cell Line, Tumor. Cells, Cultured. Down-Regulation. Galectin 1 / analysis. Galectin 1 / genetics. Gene Expression Profiling. Humans. Immunohistochemistry / methods. Membrane Proteins / genetics. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351635.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A2; 0 / CALM2 protein, human; 0 / Calmodulin; 0 / Galectin 1; 0 / Membrane Proteins; 0 / S100 Proteins; 0 / S100 calcium binding protein A10; 146909-89-9 / S100A11 protein, human; 179801-28-6 / LAPTM5 protein, human
  •  go-up   go-down


16. Muto A, Nakagawa A, Shimomura Y, Kitagawa Y, Tsurusawa M: Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro. Leuk Lymphoma; 2005 Oct;46(10):1489-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro.
  • Anti-neoplastic effects of a total of 11 agents (adriamycin, briplatin, cytarabine, dexamethasone, etoposide, 4-hydroperoxycyclophosphamide, 4-hydroperoxyifosphamide, methotrexate, predonisolone, vinblastine, vincristine) were tested on 4 cell lines (DEL, Ki-JK, SR-786, SU-DHL-1) established from pediatric ALCL cases.
  • The individual cell lines were treated with those agents at different concentrations (0.01 microM/L, 0.1 microM/L, 1 microM/L, 10 microM/L, 100 microM/L) for 1 h or 24 h, and their cellular growths were measured by the microculture tetrozolium (MTT) assay.
  • Of those anti-neoplastic agents, methotrexate, vinblastine, and vincristine were highly effective on the cell growth inhibition in all these cell lines with time- and dose-dependent manner.
  • Among them, vinblastine was found to be the most effective in 3 cell lines (DEL, Ki-JK, SR786) with 50% effective doses (ED50, concentrations causing 50% cell survival after treatment) ranging from 0.0016 to 1.27 microM/L for the 1-h treatment and 0.0002 - 0.59 microM/L for the 24-h treatment.
  • Further experiments demonstrated that vinblastine treatment induced cellular apoptosis and caused severe disruption in mitotic spindle formation on these cell lines.
  • The results support the protocol of ALCL 99 study, which uses vinblastine as one of the first-line anti-neoplastic agents for the high-risk ALCL patients in the pediatric age group.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Lymphoma, Large-Cell, Anaplastic / pathology. Vinblastine / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Humans. Tubulin / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194895.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tubulin; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


17. Tamaru J, Tokuhira M, Nittsu N, Nakamura S, Ichinohasama R, Suzuki R, Mori H, Takagi T, Suzuki T, Itami J, Itoyama S, Mikata A: Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma. Leuk Lymphoma; 2007 Jun;48(6):1127-38
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma.
  • In the WHO classification, the majority of Hodgkin-like ALCL cases as defined by the REAL classification are considered to be CHL.
  • However, establishing a histological diagnosis for the gray zone between CHL and ALCL is often confusing.
  • Expression of PAX-5/BSAP was observed in 88% (76/87) of CHL specimens and none (0/11) of ALK-positive ALCL specimens.
  • Among specimens of Hodgkin-like ALCL and ALK-negative ALCL, expression of PAX-5/BSAP was observed in 77% (20/26) and 18% (3/17), respectively.
  • Most of the PAX-5/BSAP-positive specimens were negative for Oct.2 and/or BOB.1/OBF.1 except for four CHL specimens.
  • Our results may support the WHO classification in which most cases of Hodgkin-like ALCL are classified as CHL.
  • However, the patients with Hodgkin-like ALCL with CHL-immunophenotype (PAX-5/BSAP-positive and negative for Oct.2 and/or BOB.1) did not have a favorable outcome, with a 5-year OS rate of 58%.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. B-Cell-Specific Activator Protein / genetics. Biomarkers, Tumor / genetics. Diagnosis, Differential. Female. Gene Expression Regulation, Leukemic. Humans. Male. Middle Aged. Neoplasm Staging. Octamer Transcription Factor-2 / genetics. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Retrospective Studies. Survival Analysis. Trans-Activators / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577776.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Octamer Transcription Factor-2; 0 / PAX5 protein, human; 0 / POU2AF1 protein, human; 0 / Trans-Activators; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


18. Wu F, Wang P, Zhang J, Young LC, Lai R, Li L: Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics; 2010 Jul;9(7):1616-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
  • The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), found exclusively in a subset of ALK-positive anaplastic large cell lymphoma, promotes tumorigenesis by exerting its constitutively active tyrosine kinase activity.
  • Further validation of the TNF/Fas/TRAIL pathway was performed in ALK(+) anaplastic large cell lymphoma (ALCL) cell lines with knockdown of NPM-ALK using short interference RNA, resulting in the loss of the tyrosine phosphorylation of tumor necrosis factor receptor-associated protein 1 (TRAP1) and receptor-interacting protein 1, two crucial TNF signaling molecules.
  • Functional analyses revealed that knockdown of TRAP1 facilitated cell death induced by TRAIL or doxorubicin in ALK(+) ALCL cells.
  • This suggests that down-regulation of TRAP1 in combination with TRAIL or doxorubicin might be a potential novel therapeutic strategy for ALK(+) ALCL.


19. Balachandran I, Walker JW Jr, Broman J: Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review. Diagn Cytopathol; 2010 Mar;38(3):213-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review.
  • Epstein-Barr virus (EBV) related non-Hodgkin's lymphomas of B-cell type is more common than those of T-cell origin.
  • CD30 positive Anaplastic Large Cell Lymphoma (ALCL) is a Non-Hodgkin's lymphoma (B or T cell type) that accounts for a small percentage of PTLD's.
  • ALCL of T-cell type are a spectrum of disease ranging from primary cutaneous to systemic nodal ALCL.
  • The systemic nodal ALCL is further subdivided into anaplastic lymphoma kinase-1 (ALK-1) positive or negative.
  • We present an unusual manifestation of ALK-1 negative CD30 positive ALCL in a post renal transplant patient in FNA cytology with all supportive adjuvant studies and differential diagnoses and review the cytology literature on this topic.
  • [MeSH-major] Antigens, CD30 / analysis. Kidney Transplantation / adverse effects. Lymphoma, Large-Cell, Anaplastic / pathology. Mediastinal Neoplasms / pathology. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma / diagnosis. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Immunocompromised Host. Immunohistochemistry. Male. Melanoma / diagnosis. Postoperative Complications. Prednisone / therapeutic use. Receptor Protein-Tyrosine Kinases. Remission Induction. Seminoma / diagnosis. Seminoma / secondary. Testicular Neoplasms / diagnosis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19774614.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Karikari IO, Thomas KK, Lagoo A, Cummings TJ, George TM: Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review. Pediatr Neurosurg; 2007;43(6):516-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review.
  • A biopsy of the brain revealed histologic and immunophenotypic findings characteristic of ALK-1+ anaplastic large cell lymphoma (ALCL).
  • ALCL rarely occurs in the central nervous system and poses a significant diagnostic challenge often leading to a delay in the initiation of appropriate treatment.
  • We describe a case of a rapidly deteriorating clinical course in a child with central nervous system ALCL and review the current literature on ALCL occurring in the central nervous system.
  • [MeSH-major] Activin Receptors, Type II / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / enzymology. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / enzymology


21. Bollag R, Ramalingam P, Davis B, Reid-Nicholson M: Fine needle aspiration cytology of an endotracheal mass: report of a case with an unusual presentation of anaplastic large cell lymphoma. Acta Cytol; 2010 May-Jun;54(3):328-32
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of an endotracheal mass: report of a case with an unusual presentation of anaplastic large cell lymphoma.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an uncommon hematolymphoid neoplasm characterized by malignant lymphocytes of T-cell phenotype.
  • We herein describe a case of ALCL that presented as an endotracheal mass with associated hilar lymphadenopathy.
  • In this location the diagnosis of ALCL can be especially difficult as its pleomorphic cytomorphology mimics that of a carcinoma, which is a more typical neoplasm arising in the trachea.
  • Immunohistochemical studies confirmed the diagnosis of ALCL.
  • CONCLUSION: ALCL may have an unusual presentation and involve diverse sites, including the trachea.
  • While its cytologic features are straightforward, a high index of suspicion is necessary to ensure accurate diagnosis when it presents in unusual locations.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Tracheal Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518421.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Carmichael MG: Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy. Mil Med; 2007 Jun;172(6):673-5
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
  • Anaplastic large cell lymphoma (ALCL) is 1 of 17 mature T cell neoplasms described by the World Health Organization.
  • Primary central nervous system (PCNS) ALCL represents a distinct rare form of this family of non-Hodgkin lymphoma and discussions of prognosis and management are limited to case reports and case series.
  • Therapies for this disease largely parallel that of other PCNS lymphomas.
  • We report the case of a 38-year-old male soldier who presented with a parieto-occipital mass lesion and neurological sequelae without evidence of systemic disease.
  • Pathologic evaluation of tissue from brain biopsy confirmed ALCL.
  • We elected treatment with an intensive combination of systemic and intrathecal chemotherapy with radiotherapy.
  • Tailored therapies for PCNS ALCL are unavailable and this regimen may be an option for patients who can tolerate intensive treatments.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615857.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


23. Andorsky DJ, Yamada R, Steward K, De Vos S, Said J, Timmerman J: Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells. J Clin Oncol; 2009 May 20;27(15_suppl):8526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells.
  • METHODS: PD-L1 expression was analyzed in 16 NHL cell lines by flow cytometry (FC) and in 111 lymphoma specimens by immunohistochemistry (IHC) (n=92) or FC (n=19).
  • In functional studies, irradiated anaplastic large cell lymphoma (ALCL) cells were co-cultured with allogeneic T cells in the presence of anti-PD-L1 blocking antibody, and IFNγ secretion and thymidine incorporation was used to assess T cell function and proliferation.
  • To further test tumor-T cell interactions, malignant ascites from a patient with ALK+ ALCL and peripheral blood mononuclear cells from a patient with leukemic mantle cell lymphoma, both containing PD-L1-expressing tumor cells and tumor-associated T cells, were stimulated with phytohemagglutinin (a polyclonal T cell activator) and incubated with anti-PD-L1 antibody.
  • Levels of 16 inflammatory cytokines were measured as an assessment of T cell activity.
  • RESULTS: All 9 B cell lymphoma lines were negative for PD-L1, while all 5 ALCL cell lines were strongly positive.
  • One T-cell ALL line was positive, and one peripheral T cell lymphoma was negative.
  • Strong PD-L1 staining was detected by IHC in all 14 ALCL specimens and in 83% of diffuse large B cell lymphomas (DLBCL) analyzed (n=35).
  • Activity of allogeneic T cells co-cultured with irradiated ALCL cells, as measured by IFNγ secretion and proliferation, was markedly enhanced in the presence of anti-PD-L1 blocking antibody.
  • In the autologous setting using cultures of ALCL and mantle cell lymphoma specimens containing host T cells, secretion of inflammatory cytokines by tumor-associated T cells, including GMCSF, IFNγ, IL-1, IL-6, IL-8, TNFα, and MIP1α, were increased by incubation with anti-PD-L1 antibody.
  • CONCLUSIONS: PD-L1 is highly expressed in ALCL and in a majority of DLBCL.
  • PD-L1 may play a role in thwarting an effective anti-tumor immune response and represents an attractive target for lymphoma immunotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960901.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Sano F, Tasaka T, Nishimura H, Akiyama T, Kubo Y, Matsuhashi Y, Wada H, Sugihara T, Sadahira Y: Small cell variant of anaplastic large cell lymphoma diagnosed by a novel chromosomal abnormality t(2;5;3)(p23;q35;p21) of bone marrow cells. Pathol Int; 2008 Aug;58(8):494-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant of anaplastic large cell lymphoma diagnosed by a novel chromosomal abnormality t(2;5;3)(p23;q35;p21) of bone marrow cells.
  • Because of the rarity and the morphological variations, small cell variant of anaplastic large cell lymphoma (ALCL) represents a diagnostic challenge.
  • Herein is reported a case of leukemic type of small cell variant of ALCL, in which the diagnosis was established by a cytogenetic analysis.
  • The initial differential diagnosis on bone marrow trephine biopsy sections included viral infection and peripheral T-cell lymphoma unspecified.
  • But a cytogenetic study on bone marrow cells indicated a novel complex translocation, t(2;5;3)(p23;q35;p21), which led to confirmation of anaplastic lymphoma kinase (ALK)-positive pleomorphic small to medium-sized cells scattered in bone marrow cells, on immunohistochemistry.
  • The patient achieved complete remission after four courses of combination chemotherapy, and received autologous peripheral stem cell transplantation (auto-PBSCT) after two additional courses of combination chemotherapy, but relapsed 2 months after auto-PBSCT in the bilateral lung.
  • Allogeneic stem cell transplantation led to a second remission.
  • This case demonstrates the diagnostic importance of cytogenetic study for malignant lymphoma involving bone marrow.
  • [MeSH-major] Bone Marrow Cells / pathology. Chromosomes, Human, 1-3 / genetics. Chromosomes, Human, Pair 5 / genetics. Lymphoma, Large-Cell, Anaplastic / diagnosis. Translocation, Genetic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Chromosome Banding. Diagnosis, Differential. Female. Humans. Lymphoma, T-Cell, Peripheral / diagnosis. Protein-Tyrosine Kinases / immunology. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Remission Induction. Spectral Karyotyping. Virus Diseases / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Small Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705769.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


25. Chong AL, Ngan BY, Weitzman S, Abla O: Anaplastic large cell lymphoma of the ovary in a pediatric patient. J Pediatr Hematol Oncol; 2009 Sep;31(9):702-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma of the ovary in a pediatric patient.
  • Lymphoma can rarely present as an ovarian tumor in children.
  • We describe the unusual case of a 14-year-old adolescent with a locally disseminated ovarian anaplastic large-cell lymphoma, treated with surgery followed by chemotherapy, and who remains disease free at 2 years after diagnosis.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Long QT Syndrome / chemically induced. Lymph Node Excision. Methotrexate / administration & dosage. Omentum / surgery. Ovariectomy. Postoperative Complications. Prednisone / administration & dosage. Remission Induction. Sepsis / etiology. Tumor Lysis Syndrome / etiology. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684523.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Vaid R, Cohen B: Primary cutaneous CD30 positive anaplastic large cell lymphoma in an adolescent. Pediatr Dermatol; 2009 Nov-Dec;26(6):721-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30 positive anaplastic large cell lymphoma in an adolescent.
  • We present a case of a 14-year-old boy with a large ulcerated plaque on the scalp for 6 months, who was found to have primary cutaneous CD30-positive, anaplastic kinase-negative, anaplastic large cell lymphoma with post-auricular lymphadenopathy.
  • MRI, bone marrow biopsy, and laboratory data demonstrated no other systemic involvement.
  • Very few cases of primary cutaneous CD30-positive anaplastic large cell lymphoma in the pediatric population have been reported, and our case represents one of the first pediatric patients with local lymph node involvement.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Scalp / metabolism. Scalp / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20199449.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Mosunjac MB, Sundstrom JB, Mosunjac MI: Unusual presentation of anaplastic large cell lymphoma with clinical course mimicking fever of unknown origin and sepsis: autopsy study of five cases. Croat Med J; 2008 Oct;49(5):660-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of anaplastic large cell lymphoma with clinical course mimicking fever of unknown origin and sepsis: autopsy study of five cases.
  • AIM: To describe a subset of cases with the unusual clinical and histomorphological presentation of anaplastic large cell lymphoma (ALCL) mimicking fever of unknown origin (FUO) and sepsis.
  • METHODS: A pathology database was searched using full term Systematized Nomenclature of Medicine codes for ALCL to identify 23ALCL cases from the period 1999-2006.
  • Of those, five cases that did not have a correct premortem diagnosis were further analyzed to elucidate the reasons for delayed and incorrect pre-mortem diagnosis.
  • The analyzed data included clinical presentation, duration of symptoms, duration of hospital stay, premortem presumed cause of death, white blood cell count, platelet count, anion gap and blood pH, liver enzymes (alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase), lactate, coagulation tests (prothrombin time, partial thromboplastin time, fibrinogen, D-dimers), microbiology cultures, and radiology and surgical pathology reports.
  • Autopsy reports were reviewed for description of major gross findings, initial clinical diagnosis, and cause of death.
  • RESULTS: Five fatal and pre-mortem unrecognized ALCL cases were characterized by rapid decline, with histologic findings showing predominantly extranodal involvement, intravascular lymphomatosis, and hemophagocytosis.
  • CONCLUSIONS: There is a distinct group of ALCLs with unique and specific clinical, gross autopsy, and histopathologic findings.
  • Recognition of this clinical variant may facilitate early detection and potentially timely diagnosis and therapy.
  • [MeSH-major] Fever of Unknown Origin / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis. Sepsis / etiology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2000 Apr;142(4):766-70 [10792229.001]
  • [Cites] Int J Hematol. 1997 Apr;65(3):215-26 [9114593.001]
  • [Cites] Dig Dis Sci. 2000 Nov;45(11):2240-6 [11215747.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Eur J Dermatol. 2001 May-Jun;11(3):203-8 [11358725.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2237-46 [11745277.001]
  • [Cites] Haematologica. 2002 Feb;87(2):ELT05 [11836182.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):1091-5 [12072086.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1827-32 [12419758.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):353-5 [12688357.001]
  • [Cites] Pol Merkur Lekarski. 2003 Feb;14(80):133-5 [12728673.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jun;18(6):1214-6 [12748358.001]
  • [Cites] Clin Lab Haematol. 2003 Jun;25(3):185-6 [12755796.001]
  • [Cites] Beijing Da Xue Xue Bao. 2003 Apr 18;35(2):143-5 [12920829.001]
  • [Cites] Am J Clin Pathol. 2003 Oct;120(4):617-25 [14560573.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2001-6 [15370244.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):779-82 [7248904.001]
  • [Cites] J Histochem Cytochem. 1982 Jul;30(7):713-6 [6286753.001]
  • [Cites] Hematol Oncol. 1989 Nov-Dec;7(6):441-9 [2553576.001]
  • [Cites] Arch Pathol Lab Med. 1991 Feb;115(2):188-92 [1847037.001]
  • [Cites] Am J Hematol. 1991 Jun;37(2):112-9 [1648880.001]
  • [Cites] Med Pediatr Oncol. 1993;21(9):665-9; discussion 669-70 [8413001.001]
  • [Cites] Med Klin (Munich). 1994 Jun 15;89(6):299-304 [8072452.001]
  • [Cites] J Dermatol. 1995 Oct;22(10):743-6 [8586753.001]
  • [Cites] Metabolism. 1997 Mar;46(3):306-21 [9054475.001]
  • [Cites] Am J Hematol. 1997 Mar;54(3):219-24 [9067501.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):115-7 [9448189.001]
  • [Cites] Histopathology. 1997 Dec;31(6):555-62 [9447388.001]
  • [Cites] Hum Pathol. 1999 Aug;30(8):978-81 [10452512.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3355-7 [15205267.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):461-3 [15621840.001]
  • [Cites] Int Urol Nephrol. 2004;36(3):393-6 [15783113.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Diagn Cytopathol. 2005 Aug;33(2):106-9 [16007654.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):806-11 [16084951.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6221-4 [16273656.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):1000-6 [16189700.001]
  • [Cites] Histopathology. 2006 Apr;48(5):481-504 [16623775.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Jan;3(1):24-35 [17205072.001]
  • [Cites] Am J Clin Pathol. 2007 Mar;127(3):458-64 [17276937.001]
  • [Cites] J Ky Med Assoc. 2000 Apr;98(4):161-5 [10816985.001]
  • (PMID = 18925700.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Other-IDs] NLM/ PMC2582359
  •  go-up   go-down


28. Monaco S, Tsao L, Murty VV, Nandula SV, Donovan V, Oesterheld J, Bhagat G, Alobeid B: Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase. Am J Hematol; 2007 Jan;82(1):59-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase.
  • Pediatric ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is usually associated with a favorable prognosis.
  • ALK+ ALCL associated with a leukemic phase is uncommon, but has been associated with an aggressive clinical course and unfavorable prognosis.
  • Overexpression of c-myc has been shown to be a consistent finding in ALK+, but not ALK-negative ALCL (ALK- ALCL), and the c-myc gene is considered a downstream target of deregulated ALK signaling.
  • We describe a pediatric ALK+ ALCL with a leukemic phase at relapse.
  • Lymphoma cells showed aberrant ALK expression and c-myc overexpression.
  • In addition to the characteristic t(2;5)(p23;q35) translocation, a t(3;8)(q26.2;q24) translocation was also present, and c-myc gene rearrangement was confirmed by FISH analysis.
  • The findings in this case demonstrate the association of peripheral blood leukemic involvement and aggressive clinical course, and suggest that other factors, such as c-myc rearrangement, may be responsible for the aggressive clinical behavior in ALK+ ALCL.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Chromosomes, Human, Pair 8 / genetics. Gene Rearrangement. Leukemia / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955462.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


29. Rosolen A, Pillon M, Garaventa A, Burnelli R, d'Amore ES, Giuliano M, Comis M, Cesaro S, Tettoni K, Moleti ML, Tamaro P, Visintin G, Zanesco L: Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer; 2005 Nov 15;104(10):2133-40
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol.
  • BACKGROUND: Childhood anaplastic large cell lymphoma (ALCL) is a well defined entity with a rather poor prognosis.
  • Different approaches have been adopted in the treatment of ALCL in various cooperative trials, including short high-dose intensive therapy and leukemia-like protocols.
  • In the early 1990s, the Italian Association of Pediatric Hematology and Oncology (AIEOP) initiated a multicenter trial for the treatment of ALCL based on a modified LSA2-L2 protocol.
  • METHODS: Thirty-four consecutive eligible children with newly diagnosed ALCL were enrolled in the AIEOP LNH-92 protocol.
  • Treatment was comprised of an induction of remission phase, followed by consolidation and maintenance for a total duration of 24 months, independently of disease stage.
  • RESULTS: Thirty of 34 patients (88%) achieved complete disease remission and 8 patients experienced disease recurrence.
  • CONCLUSIONS: The leukemia-like protocol AIEOP LNH-92 was found to be an effective treatment for childhood ALCL.
  • Its long duration may be beneficial to specific patient subgroups, but optimal treatment duration in ALCL remains to be elucidated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease-Free Survival. Female. Humans. Immunohistochemistry. Leukemia / therapy. Male. Methotrexate / therapeutic use. Neoplasm Staging. Prednisone / therapeutic use. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16211546.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


30. Ito M, Zhao N, Zeng Z, Chang CC, Zu Y: Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126. Cancer Gene Ther; 2010 Sep;17(9):633-44
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126.
  • Abnormal expression of anaplastic lymphoma kinase (ALK) gene is an important pathogenic factor for anaplastic large cell lymphoma (ALCL).
  • To study the function of ALK, an inducible short hairpin RNA (shRNA) system was stably introduced into cultured human ALCL cells.
  • This synergistic effect was also observed when measuring cell proliferation, apoptosis, and in vitro cell colony formation.
  • Importantly, the combination of ALK gene silencing and U0126 had a prolonged inhibitory effect, preventing recovery of ALCL cell growth even after treatments were removed.
  • Moreover, this synergistic inhibitory effect was confirmed in vivo using a mouse model with xenografted ALCL tumors.
  • Our findings indicate that combining cellular ALK gene silencing with a low dose of U0126 may prove to be an effective and more specific therapeutic approach to treating ALCL.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2001 Sep;108(6):851-9 [11560954.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Science. 2002 May 17;296(5571):1265-9 [12016303.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):957-63 [12963974.001]
  • [Cites] Oligonucleotides. 2003;13(5):365-73 [15000827.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2617-29 [14968112.001]
  • [Cites] Blood. 1989 Jun;73(8):2155-64 [2525056.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):937-42 [8387578.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):899-908 [8164040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6 [8633037.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2901-10 [9376569.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18623-32 [9660836.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] Nat Med. 2005 Jun;11(6):623-9 [15895073.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5281-93 [16009947.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7628-34 [16140928.001]
  • [Cites] Blood. 2006 Jan 15;107(2):689-97 [16189272.001]
  • [Cites] Cancer Invest. 2007 Jun;25(4):240-8 [17612934.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):30-7 [17987349.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2139-46 [18390968.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2439-49 [18614762.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • (PMID = 20448669.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA126752-03; United States / NCI NIH HHS / CA / K22 CA113493-03; United States / NCI NIH HHS / CA / CA126752-03; United States / NCI NIH HHS / CA / 1K22CA113493; United States / NCI NIH HHS / CA / 5P50CA126752; United States / NCI NIH HHS / CA / P50 CA126752; United States / NCI NIH HHS / CA / R01 CA151955; United States / NCI NIH HHS / CA / CA113493-03; United States / NCI NIH HHS / CA / K22 CA113493; United States / NCI NIH HHS / CA / CA113493-01A2; United States / NCI NIH HHS / CA / K22 CA113493-01A2; United States / NCI NIH HHS / CA / K22 CA113493-02; United States / NCI NIH HHS / CA / CA113493-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Butadienes; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / RNA, Small Interfering; 0 / U 0126; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS167595; NLM/ PMC2919633
  •  go-up   go-down


31. Salama S: Primary "cutaneous" T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review. Am J Dermatopathol; 2005 Jun;27(3):217-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary "cutaneous" T-cell anaplastic large cell lymphoma, CD30+, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review.
  • Posttransplantation lymphoproliferative disorders (PTLD) presenting clinically in the skin are rare and usually of B-cell phenotype.
  • Only 7 cases of cutaneous T-cell PTLD have been previously reported, mostly mycosis fungoides type, with no known cases of "cutaneous" presentation by CD30 (Ki-1) anaplastic large cell lymphoma (ALCL).
  • Initial biopsy showed ALCL involving the dermis with a background rich in neutrophils.
  • The neoplastic cells were of T-cell phenotype, strongly CD30 with typical staining, and BCL-2 positive, but P53 negative.
  • Twenty-two months following diagnosis, he died of cardiac failure with terminal myocardial infarct.
  • There was however no clinical evidence of systemic spread of the lymphoma.This report adds to the clinical and morphologic spectrum of these rare "cutaneous" lymphomas of T-cell lineage arising in the posttransplantation setting, and suggests that EBV does not play a role in their pathogenesis.
  • [MeSH-major] Immunocompromised Host. Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Neutrophils / immunology. Skin Neoplasms / immunology
  • [MeSH-minor] Antigens, CD30 / metabolism. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Panniculitis / etiology. Panniculitis / metabolism. Panniculitis / pathology. Polymerase Chain Reaction. Subcutaneous Tissue / pathology


32. Song HH, Baik GH, Kwon JH, Lee KS, Choi YH, Choi KC, Park YE: A case of primary gastric CD30-positive anaplastic large-cell lymphoma. J Korean Med Sci; 2005 Dec;20(6):1062-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary gastric CD30-positive anaplastic large-cell lymphoma.
  • Gastric CD30-positive anaplastic large-cell lymphoma is a very rare disease.
  • We report here on a case of primary gastric anaplastic large-cell lymphoma.
  • The gross finding of the resected stomach was an 8 x 4.5 cm sized ulceroinfiltrative lesion at the pyloric antrum along the lesser curvature.
  • The microscopic examination revealed diffuse and solid proliferations of large atypical cells with pleomorphic nuclei.
  • Immunohistochemically, the tumor cells were positive for CD30, vimentin and CD3, and this was a finding compatible with anaplastic large-cell lymphoma.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Gut. 2001 Feb;48(2):269-71 [11156652.001]
  • [Cites] Pathol Int. 2004 Jul;54(7):503-9 [15189504.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Hum Pathol. 1990 Jun;21(6):624-9 [1693592.001]
  • [Cites] Dig Dis Sci. 1998 Feb;43(2):300-5 [9512121.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):541-9 [8299075.001]
  • [Cites] Pathol Int. 1994 Feb;44(2):164-9 [8025656.001]
  • [Cites] Blood. 1995 Jan 1;85(1):1-14 [7803786.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1805-12 [8859196.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2517-23 [1330283.001]
  • (PMID = 16361823.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2779310
  •  go-up   go-down


33. Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A: Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol; 2009 Feb 20;27(6):897-903
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.
  • PURPOSE: To compare the efficacy and safety of two methotrexate doses and administration schedules in children with anaplastic large-cell lymphoma (ALCL).
  • PATIENTS AND METHODS: This randomized trial for children with ALCL was based on the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Muenster 90 (NHL-BFM90) study protocol and compared six courses of methotrexate 1 g/m2 over 24 hours and an intrathecal injection (IT) followed by folinic acid rescue at 42 hours (MTX1 arm) with six courses of methotrexate 3 g/m2 over 3 hours followed by folinic acid rescue at 24 hours without IT (MTX3 arm).
  • This trial involved most European pediatric/lymphoma study groups and a Japanese group.
  • RESULTS: Overall, 352 patients (96% ALK positive) were recruited between 1999 and 2005; 175 were randomly assigned to the MTX1 arm, and 177 were assigned to the MTX3 arm.
  • CONCLUSION: The results of the NHL-BFM90 study were reproduced in this large international trial.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Hukin J, Davey A, Wong P, Hendson G, Aquino-Parsons C, Wu J, Sargent M: Asynchronous burst-suppression in a child with callosal Ki-1 anaplastic large cell lymphoma. Neurology; 2005 Sep 27;65(6):947-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asynchronous burst-suppression in a child with callosal Ki-1 anaplastic large cell lymphoma.
  • A 13-year-old girl with Ki-1 anaplastic large cell lymphoma (Ki-1ALCL) bulky deposits in the brain developed raised intracranial pressure and coma associated with asynchronous burst-suppression following standard dose cranial irradiation.
  • [MeSH-major] Brain Neoplasms / complications. Coma / drug therapy. Coma / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Radiotherapy / adverse effects. Substance Withdrawal Syndrome / complications


35. Kumar S, Wanchu A, Sharma A, Mukherjee K, Radotra BD, Gupta V, Singh S: Spinal cord compression caused by anaplastic large cell lymphoma in an HIV infected individual. J Cancer Res Ther; 2010 Jul-Sep;6(3):376-8
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression caused by anaplastic large cell lymphoma in an HIV infected individual.
  • Lymphomas occur with an increased frequency in patients with Human Immunodeficiency Virus (HIV) infection.
  • These are usually high-grade immunoblastic lymphomas and primary central nervous system lymphomas.
  • Anaplastic large cell lymphoma (ALCL) is a distinct type of non-Hodgkin's lymphoma.
  • We describe here an uncommon presentation of this relatively rare lymphoma in the form of spinal cord compression syndrome in a young HIV infected individual.
  • [MeSH-major] HIV Infections / complications. Lymphoma, Large-Cell, Anaplastic / complications. Spinal Cord Compression / etiology


36. Ozkaynak MF: Favorable outcome of primary CNS anaplastic large cell lymphoma in an immunocompetent patient. J Pediatr Hematol Oncol; 2009 Feb;31(2):128-30
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome of primary CNS anaplastic large cell lymphoma in an immunocompetent patient.
  • A 9-year-old immunocompetent male patient with primary central nervous system anaplastic large cell lymphoma was treated with 5 cycles of intensive chemotherapy including high-dose Ara-C, high-dose methotrexate, etoposide, and carmustine along with intraventricular chemotherapy followed by high-dose thiotepa and carboplatin with autologous peripheral blood hematopoietic stem cell transplantation.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Humans. Immunocompetence. Male. Peripheral Blood Stem Cell Transplantation. Remission Induction / methods. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194199.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Balamurugan S, Rajasekar B, Rao RR: Anaplastic large-cell lymphoma with florid granulomatous reaction: a case report and review of literature. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):69-70
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell lymphoma with florid granulomatous reaction: a case report and review of literature.
  • Granulomatous reactions have been reported in association with lymphomas, more often with Hodgkins disease than with Non-Hodgkins Lymphoma.
  • Not many reports are available on the association of anaplastic large-cell lymphoma with sarcoid-type granuloma.
  • Herein, we report a case of an elderly female with generalized lymphadenopathy who had a florid granulomatous reaction almost masking the lymphoma cells in the lymph node biopsy.
  • A detailed clinical history, careful histological examination and immunohistochemistry helped in attaining the correct diagnosis.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136786.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


38. Lu Y, Zhao X, Wang E, Chen W, Huang Q: ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". Leuk Res; 2010 Apr;34(4):475-82
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase".
  • CD30-positive anaplastic large cell lymphoma (ALCL) is a distinctive malignant large cell lymphoma of T-cell lineage, often presenting in lymph node or extranodal sites.
  • ALCL cases with extensive bone marrow and peripheral blood involvement manifested as "leukemic phase" are extremely rare and the most of those cases reported are anaplastic large cell lymphoma kinase (ALK) positive ALCL in childhood population.
  • Here we report four adult cases of ALK-negative ALCL with extensive bone marrow and peripheral blood involvement manifested as "leukemic phase".
  • Circulating large lymphoma cells varied from 20 to 80% in peripheral blood and bone marrow biopsy showed various nodular or interstitial infiltrates.
  • By reviewing the clinicopathologic data of previously reported ALCL cases with extensive bone marrow and peripheral blood involvement, there appears to be of large variations in regard to the patient's age, morphologic variants, immunophenotypic or genotypic characteristics of the disease.
  • While most cases of ALCL with peripheral blood and bone marrow involvement were ALK-positive or carrying t(2;5) translocation, rare ALK-negative cases were also present.
  • Leukemic ALCL patients usually have unfavourable prognosis, regardless of ALK expression.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19695703.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


39. Tschiedel E, Grasemann H, Ratjen F: Mycobacterium chelonae in a CF patient with anaplastic large cell lymphoma. J Cyst Fibros; 2006 May;5(2):133-6
MedlinePlus Health Information. consumer health - Cystic Fibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycobacterium chelonae in a CF patient with anaplastic large cell lymphoma.
  • A 13-year-old patient with cystic fibrosis was diagnosed with anaplastic large cell lymphoma.
  • Despite massive immunosuppression, the patient did not show evidence of mycobacterial invasive disease.
  • [MeSH-major] Cystic Fibrosis / complications. Lymphoma, Large B-Cell, Diffuse / complications. Mycobacterium Infections, Nontuberculous / complications. Mycobacterium chelonae / isolation & purification

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Mycobacterium Chelonae.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403492.001).
  • [ISSN] 1569-1993
  • [Journal-full-title] Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • [ISO-abbreviation] J. Cyst. Fibros.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


40. Rannan-Eliya YF, Pulford K, Johnson R, Peart I, Kokai G, Baillie C, Ait-Tahar K, Pizer B: Isolated cutaneous anaplastic large cell lymphoma progressing to severe systemic disease with myocardial involvement and central nervous system infiltration. Pediatr Blood Cancer; 2008 Apr;50(4):879-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated cutaneous anaplastic large cell lymphoma progressing to severe systemic disease with myocardial involvement and central nervous system infiltration.
  • Anaplastic large cell lymphoma (ALCL) is a rare tumor comprising around 10-15% of childhood lymphomas.
  • We describe the case of a female who initially presented with localized skin disease associated with an insect bite.
  • However, she subsequently relapsed with widespread systemic ALK-positive ALCL that included lymphoma deposits in the myocardium, a very rare manifestation.
  • Her disease responded well to chemotherapy but she later developed a fatal relapse in the CNS.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Heart Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Echocardiography, Transesophageal. Fatal Outcome. Female. Humans. Myocardium. Oncogene Proteins, Fusion / biosynthesis. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / immunology. Protein-Tyrosine Kinases / biosynthesis. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / immunology. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17914741.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


41. Lamant L, Pileri S, Sabattini E, Brugières L, Jaffe ES, Delsol G: Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica; 2010 Mar;95(3):449-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases.
  • BACKGROUND: Skin involvement is frequent in ALK-positive anaplastic large cell lymphomas.
  • DESIGN AND METHODS: We retrospectively investigated five cases of ALK-positive anaplastic large cell lymphoma who presented with skin lesions occurring after an insect bite.
  • Biopsies were immunostained with antibodies against CD30, ALK, T- and B-cell antigens.
  • In four cases the correct diagnosis was delayed due to misinterpretation of the findings as a reactive infiltrate in the skin (n=2) or lymph nodes (n=2); all cases subsequently showed small numbers of cells with nuclear and cytoplasmic staining for ALK.
  • The final diagnoses were lymphohistiocytic variant (n=3) and composite common/small cell type (n=2) anaplastic large cell lymphoma.
  • Two patients died, one of pneumonia and the other of disseminated disease.
  • CONCLUSIONS: In these cases the sequence of events between the insect bites and the occurrence of both skin lesions and satellite lymphadenopathy suggest a direct relationship between the bite and the presentation with anaplastic large cell lymphoma.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Insect Bites and Stings.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1999 Dec;135(12):1503-7 [10606056.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):879-81 [17914741.001]
  • [Cites] Haematologica. 2000 Sep;85(9):978-81 [10980638.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):422-8 [11048978.001]
  • [Cites] Histopathology. 2000 Dec;37(6):501-8 [11122431.001]
  • [Cites] Rinsho Ketsueki. 2000 Dec;41(12):1273-6 [11201153.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2185-93 [11395396.001]
  • [Cites] J Am Acad Dermatol. 2001 Oct;45(4):569-78 [11568749.001]
  • [Cites] Arch Dermatol. 2003 Dec;139(12):1601-7 [14676078.001]
  • [Cites] Blood. 1986 Nov;68(5):1042-9 [3490284.001]
  • [Cites] Ann Pathol. 1986;6(4-5):345-7 [3545243.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Jpn J Cancer Res. 1997 Jan;88(1):82-7 [9045900.001]
  • [Cites] Arch Dermatol. 1997 Sep;133(9):1081-6 [9301584.001]
  • [Cites] J Cutan Pathol. 1997 Sep;24(8):457-61 [9331890.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):875-86 [9736036.001]
  • [Cites] Am J Hematol. 1998 Dec;59(4):309-15 [9840912.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1138-44 [9886332.001]
  • [Cites] Blood. 1965 Sep;26:257-68 [14332055.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):212-8 [15754300.001]
  • [Cites] Arch Dermatol. 2006 May;142(5):587-95 [16702496.001]
  • [Cites] J Dermatol Sci. 2007 Mar;45(3):153-60 [17169531.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):263-8 [10685647.001]
  • (PMID = 19951975.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2833075
  •  go-up   go-down


42. Escobosa Sánchez OM, Herrero Hernández A, Acha García T: [Endobronchial anaplastic large cell lymphoma in childhood]. An Pediatr (Barc); 2009 May;70(5):449-52
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endobronchial anaplastic large cell lymphoma in childhood].
  • [Transliterated title] Linfoma anaplásico de células grandes endobronquial en la infancia.
  • Anaplastic large cell lymphoma is a very rare disease in childhood.
  • The most common location of this lymphoma is lymph node and skin, with endobronchial involvement being extremely rare.
  • We report a case of a 10-year-old boy diagnosed by chance with an endobronchial anaplastic large cell lymphoma, while he was being investigated for a a benign bone disease, due to the initial absence of respiratory symptoms.
  • [MeSH-major] Bronchial Neoplasms. Lymphoma, Large-Cell, Anaplastic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375996.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


43. Yang HB, Li J, Shen T: Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review. Acta Haematol; 2007;118(3):188-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review.
  • To our knowledge, only eleven cases of primary anaplastic large cell lymphoma (ALCL) of the lung have previously been reported.
  • We describe here another two cases of primary pulmonary ALCL that developed in two Chinese women.
  • A comprehensive workup failed to show disease outside the chest.
  • CD30-positive ALCL was demonstrated by histopathological studies of the lung tissue.
  • Primary pulmonary lymphoma is a great challenge for pneumologists since the clinical presentations and radiological findings are nonspecific.
  • Appropriate invasive biopsy is necessary for early diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD30 / metabolism. Asian Continental Ancestry Group. Biopsy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17934256.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD30; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 15
  •  go-up   go-down


44. Chen RF, Chen CT, Liao HT, Chen CH, Chen YR: Primary cutaneous anaplastic large cell lymphoma of the face presenting as posttraumatic maxillary sinusitis. J Craniofac Surg; 2008 Nov;19(6):1597-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma of the face presenting as posttraumatic maxillary sinusitis.
  • Primary cutaneous anaplastic large cell lymphoma (ALCL) is an uncommon disease.
  • It has various presentations that may mislead the diagnosis and cause delay of treatment.
  • The patient was first treated for maxillary sinusitis according to clinical history, but the pathology turned out to be primary cutaneous ALCL.
  • The presentations of primary cutaneous ALCL of the face may mimic posttraumatic maxillary sinusitis.
  • [MeSH-major] Cheek / pathology. Facial Neoplasms / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Facial Injuries / diagnosis. Follow-Up Studies. Humans. Male. Maxillary Fractures / diagnosis. Maxillary Sinusitis / diagnosis. Soft Tissue Infections / diagnosis. Wounds, Nonpenetrating / diagnosis. Zygomatic Fractures / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098559.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Buxton D, Bacchi CE, Gualco G, Weiss LM, Zuppan CW, Rowsell EH, Huang Q, Wang J: Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases. Am J Clin Pathol; 2009 Apr;131(4):574-9
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases.
  • By using conventional paraffin immunoperoxidase staining and tissue microarrays, we retrospectively investigated CD99 expression in a series of 160 anaplastic large cell lymphoma (ALCL) cases.
  • Of the 160 cases, 103 (64.4%) were positive for CD99.
  • CD99 expression was present in 96 (64.4%) of 149 of the common type, 4 (80%) of 5 of the small cell variant, and 3 (50%) of 6 of the lymphohistiocytic variant cases.
  • CD99 expression was slightly more frequent in anaplastic large cell lymphoma kinase (ALK)+ cases compared with ALK- cases (43/54 [80%] vs 44/81 [54%]).
  • With 2 exceptions, ALK+ ALCL was seen only in patients younger than 41 years.
  • We conclude that CD99 is frequently expressed in ALCL, with a slightly increased frequency in the younger age ALK+ cases.
  • Nodal and extranodal ALCL should be considered in the differential diagnosis when a CD99+ neoplasm is encountered.
  • [MeSH-major] Antigens, CD / biosynthesis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / biosynthesis. Lymphoma, Large-Cell, Anaplastic / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289593.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


46. Ng A, Hobson R, Williams D, Morland B: Anaplastic large cell lymphoma of bone--is it a bad tumor? Pediatr Blood Cancer; 2007 Apr;48(4):473-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma of bone--is it a bad tumor?
  • A teenage boy presented with a CD30-positive anaplastic large cell lymphoma (ALCL) affecting his scapula and was successfully treated with chemotherapy.
  • A further review of 11 ALCL cases with bony involvement treated in the UK since 1990, including two with primary bone disease, did not suggest an unfavorable treatment outcome.
  • This finding will need to be confirmed by further study on a larger patient cohort with primary bone ALCL.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Scapula / pathology
  • [MeSH-minor] Activin Receptors, Type II / analysis. Activin Receptors, Type II / genetics. Adolescent. Antigens, CD30 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Child. Child, Preschool. Cohort Studies. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Great Britain / epidemiology. Humans. Ifosfamide / administration & dosage. Infant. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Prognosis. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078220.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 11
  •  go-up   go-down


47. Papalas JA, Van Mater D, Wang E: Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young. Am J Dermatopathol; 2010 Dec;32(8):821-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young.
  • Cutaneous anaplastic large-cell lymphoma belongs to the class of primary cutaneous CD30-positive lymphoproliferative disorders.
  • We describe 2 cases (one which clinically presented as cellulitis, and another arising in a patient with Hodgkin lymphoma) and review the clinicopathologic features of cases reported in the literature.
  • Ten percent of patients experience extracutaneous disease progression and 18% of patients are dead at 10 months.
  • Immunophenotypically, the anaplastic large cells demonstrate loss of pan-T cell antigens, CD2, CD3, CD5, and CD7, with 65% of cases expressing CD4 and 29% of cases expressing CD8.
  • In the clinical context of a progressive ulcerating lesion in younger or immunocompromized patients, it is important for the pathologist when presented with a skin specimen demonstrating a neutrophil-rich inflammatory background to include the pyogenic variant of anaplastic large-cell lymphoma.
  • We hope to increase awareness of this rare CD30-positive lymphoproliferative disorder subtype by better defining the clinical spectrum in which this entity can present.
  • [MeSH-major] Immunocompromised Host. Lymphoma, Primary Cutaneous Anaplastic Large Cell / immunology. Neutrophils / immunology. Skin / immunology. Skin Neoplasms / immunology


48. Mencía-Gutiérrez E, Gutiérrez-Díaz E, Salamanca J, Martínez-González MA: Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL). Int J Dermatol; 2006 Jun;45(6):766-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL).
  • AIM: To report an unusual case of cutaneous presentation on the eyelid of systemic (or nodal), CD30+, anaplastic large-cell lymphoma (ALCL).
  • RESULTS: The histopathologic and immunohistochemical diagnosis was ALCL, T-cell phenotype, strongly positive for CD43 and CD30, and negative for CD3, anaplastic lymphoma kinase (ALK), and B-cell antigens.
  • CONCLUSIONS: Primary, systemic, CD30+, ALK-negative, ALCL presentations generally have a poor prognosis and tend to occur in older individuals, although the clinical outcome is highly variable and difficult to predict in individual cases.
  • Only three cases of ALCL have been described in the ocular adnexae and none was ALK-negative.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / analysis
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD30 / analysis. Combined Modality Therapy. Humans. Lymphatic Metastasis. Male. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796648.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


49. Duplantier MM, Lamant L, Sabourdy F, de Reynies A, Delsol G, Espinos E: Serpin A1 is overexpressed in ALK+ anaplastic large cell lymphoma and its expression correlates with extranodal dissemination. Leukemia; 2006 Oct;20(10):1848-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serpin A1 is overexpressed in ALK+ anaplastic large cell lymphoma and its expression correlates with extranodal dissemination.
  • Anaplastic large cell lymphoma (ALCL) is a distinct subtype of non-Hodgkin's lymphoma.
  • Most of ALCLs (85%) carry a chromosomal translocation involving different partners in the 5' portion, and the anaplastic lymphoma kinase (ALK) receptor kinase domain in the 3' portion.
  • These translocations induce the ectopic expression of X-ALK proteins, thought to be involved in lymphomagenesis, through the dysregulation of cell proliferation and apoptotic pathways.
  • In the present study, based on several ALK+ and ALK- ALCL cell lines and biopsy specimens, we showed that serpin A1, a secretory glycoprotein, was overexpressed in ALK+ ALCL cell lines and ALK+ tumors at both the transcriptional and translational levels.
  • These data, together with the pattern of expression of serpin A1 we observed in ALK+ tumors, suggest that serpin A1 has an invasion-promoting effect in ALK+ ALCL.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. alpha 1-Antitrypsin / genetics
  • [MeSH-minor] Adult. Biopsy. Cell Line, Tumor. Child. Humans. Lymph Nodes / pathology. Neoplasm Invasiveness. Protein Biosynthesis. Protein-Tyrosine Kinases / genetics. RNA, Messenger / analysis. Receptor Protein-Tyrosine Kinases. Transcription, Genetic. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900211.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SERPINA1 protein, human; 0 / alpha 1-Antitrypsin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


50. Li S, Lee AK: Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction? Int J Clin Exp Pathol; 2009;3(1):117-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silicone implant and primary breast ALK1-negative anaplastic large cell lymphoma, fact or fiction?
  • A series of anecdotal case reports and a recent epidemiological case-control study have suggested a possible association between silicone implant and the development of primary breast ALK1-negative anaplastic large cell lymphoma (ALCL), a rare type of peripheral T-cell lymphoma.
  • In this report, we describe an additional case of primary breast ALK1-negative ALCL in the fibrous capsule and cystic fluid of silicone breast implant in a 58 year old woman who underwent breast reconstructive surgery after lumpectomy for her infiltrating breast adenocarcinoma.
  • Morphologically and immunohistochemically, the lymphoma cells may be confused with recurrent infiltrating breast adenocarcinoma or other non-hematolymphoid malignancies.
  • Molecular studies were needed to determine T-lineage differentiation of the malignant lymphoma cells.
  • We will also review the case reports and case series published in the English literature and discuss our current understanding of silicone implant in primary breast ALK1-negative ALCL.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Breast Implants / adverse effects. Breast Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Diagnosis, Differential. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Reconstructive Surgical Procedures

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):407-13 [18480397.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Am J Hematol. 2009 Mar;84(3):133-9 [19199367.001]
  • [Cites] Plast Reconstr Surg. 2009 Mar;123(3):790-3 [19319041.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):831-3 [19330656.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):918-24 [19373599.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):301-6 [19318917.001]
  • [Cites] Clin Breast Cancer. 2009 Aug;9(3):145-54 [19661037.001]
  • [Cites] Ann Oncol. 2009 Dec;20(12):1993-9 [19570964.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Epidemiology. 2001 May;12(3):321-6 [11337605.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Haematologica. 2004 Apr;89(4):ELT01 [15075114.001]
  • [Cites] J Am Acad Dermatol. 1995 Jun;32(6):939-42 [7751462.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):712-7 [7755157.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1341-9 [9308703.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):557-60 [16622125.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Int J Hematol. 2008 Jun;87(5):491-7 [18414980.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008 Jul;61(7):822-5 [17509956.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • (PMID = 19918336.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  • [Other-IDs] NLM/ PMC2776268
  • [Keywords] NOTNLM ; ALCL / ALK1 / Breast implant / anaplastic large cell lymphoma / silicone
  •  go-up   go-down


51. Shimoyama Y, Sakakibara A, Kawai K, Nagasaka T, Nakamura S: Molecular diagnosis of malignant lymphoma: mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of malt. Nagoya J Med Sci; 2006 Jan;68(1-2):1-8
Genetic Alliance. consumer health - Mantle cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnosis of malignant lymphoma: mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of malt.
  • Malignant lymphoma is a heterogeneous category embracing three major types of lymphoid neoplasms: B cell neoplasms, T and NK cell neoplasms, and Hodgkin lymphoma.
  • Within each type, distinct disease entities are defined based on a combination of morphology, immunophenotype, genetic features and clinical syndromes, the emphasis on which represents a new paradigm in the lymphoma classification of the World Health Organization (WHO).
  • These lymphoma entities often have distinctive cytogenetic abnormalities, usually involving translocations that place a potential cellular oncogene under the influence of the immunoglobulin in some low-grade B-cell lymphomas.
  • Both pathologists and oncologists are now concerned with better understanding each disease entity and its spectrum of morphology, genetic events, and clinical behaviors.
  • Over the last decade, significant progress has been made in the molecular characterizations of mantle cell lymphoma, anaplastic large cell lymphoma, and marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), which have not only provided insights into the pathogenesis of lymphomas, but also valuable data that could lead to therapies based on their clinical behavior.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Mantle-Cell / diagnosis. Molecular Diagnostic Techniques

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579170.001).
  • [ISSN] 0027-7622
  • [Journal-full-title] Nagoya journal of medical science
  • [ISO-abbreviation] Nagoya J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 136601-57-5 / Cyclin D1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 23
  •  go-up   go-down


52. Iyengar P, Reid-Nicholson M, Moreira AL: Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma. Diagn Cytopathol; 2006 Apr;34(4):298-302
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma.
  • Anaplastic large-cell lymphoma (ALCL) is a rare T-cell lymphoma typically seen in children and young adults.
  • We herein report a case of ALCL arising in the breast of a 36-yr-old pregnant woman.
  • We would like to highlight the cytologic and histologic features of ALCL, as this case was initially misdiagnosed as a ductal carcinoma.
  • Differential diagnosis with other tumors is also discussed.
  • [MeSH-major] Breast / pathology. Carcinoma, Ductal, Breast / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pregnancy


53. Kesler MV, Paranjape GS, Asplund SL, McKenna RW, Jamal S, Kroft SH: Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases. Am J Clin Pathol; 2007 Aug;128(2):314-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases.
  • We report our experience with flow cytometric (FC) analysis of 29 cases of anaplastic large cell lymphoma (ALCL).
  • Morphologic analysis of processed cytocentrifuged preparations demonstrated neoplastic cells in 28 cases.
  • Of 21 cases, 13 were anaplastic lymphoma kinase (ALK)+, all of which were CD4+, vs 5 of 8 ALK - cases (P = .042).
  • Most ALCLs can be detected and characterized by multiparameter FC analysis.
  • [MeSH-major] Antigens, CD / analysis. Flow Cytometry / methods. Lymphoma, Large B-Cell, Diffuse / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Child. Child, Preschool. Female. Humans. Light. Male. Middle Aged. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Scattering, Radiation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638668.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


54. Bittencourt AL, Rothers S, Boente P, Santos R: Primary cutaneous eosinophil-rich anaplastic large cell lymphoma: report of an unusual case and literature review. J Cutan Med Surg; 2008 Mar-Apr;12(2):88-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous eosinophil-rich anaplastic large cell lymphoma: report of an unusual case and literature review.
  • BACKGROUND: Cutaneous, neutrophil-rich anaplastic large cell lymphoma (ALCL) is an uncommon variant of ALCL that may be confused with inflammatory dermatoses.
  • OBJECTIVE AND METHODS: We describe an eosinophil-rich variant of ALCL occurring on the left ear without systemic involvement.
  • The lesion had inflammatory characteristics, which led initially to a histological diagnosis of an inflammatory process.
  • Two months later, a second biopsy diagnosed eosinophil-rich variant of ALCL.
  • We discuss the clinicopathological findings and the differential diagnosis CONCLUSIONS: To the best of our knowledge, the occurrence of a cutaneous, eosinophil-rich variant of ALCL has not been previously reported.
  • It is important to alert pathologists to this variant of ALCL so that this possibility may be considered in the early differential diagnosis of inflammatory cutaneous conditions.
  • [MeSH-major] Ear Neoplasms / metabolism. Ear, External. Eosinophils / metabolism. Lymphoma, Primary Cutaneous Anaplastic Large Cell / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Skin Diseases / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346406.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


55. Mussolin L, Pillon M, d'Amore ES, Santoro N, Lombardi A, Fagioli F, Zanesco L, Rosolen A: Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia; 2005 Sep;19(9):1643-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma.
  • Anaplastic large cell lymphoma (ALCL) harbors the reciprocal chromosomal translocation t(2;5)(p23;q35) in approximately 80% of the cases.
  • The genes involved are nucleophosmin (NPM) and anaplastic lymphoma kinase (ALK) and the resulting chimeric NPM-ALK protein is thought to play a key role in the pathogenesis of t(2;5) positive ALCL.
  • Few data on bone marrow (BM) involvement in ALCL have been published and they mostly rely on morphological examination of BM smears.
  • We studied 52 ALCL for NPM-ALK expression by RT-PCR: 47/52 biopsies were positive.
  • In 41 of the 47 cases we obtained the BM at diagnosis and investigated the prevalence of minimal BM infiltration by RT-PCR and real-time PCR.
  • Minimal disseminated disease was positive in 25/41 patients (61%), of whom six had morphologically infiltrated BM.
  • Survival analysis demonstrated a 5-year progression-free survival of 41 +/- 11% for patients with molecularly positive BM vs 100% for patients with negative BM (P = 0.001).
  • These results suggest that minimal BM involvement at diagnosis is a common event in pediatric ALCL and that minimal BM disease monitoring could identify patients at risk of relapse.
  • [MeSH-major] Bone Marrow / metabolism. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049513.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


56. Cağlar K, Akyüz C, Uner A, Kutluk T, Yalçin B, Varan A, Büyükpamukçu M: Anaplastic large cell lymphoma in a child presenting with cutaneous nodules and blisters. Turk J Pediatr; 2005 Apr-Jun;47(2):188-90
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma in a child presenting with cutaneous nodules and blisters.
  • In another hospital, histopathological diagnosis of a skin biopsy was reported to be consistent with tuberculosis and she was treated with antimycobacterial drugs.
  • At our center, histopathological diagnosis was anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL).
  • Eight months after initial admisision, she experienced cutaneous recurrence of disease while on maintenance protocol.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052864.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


57. Chen CH, Chen SW, Shen WL, Chen TY, Tsao CJ, Huang WT: Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Int J Hematol; 2007 Feb;85(2):105-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
  • Anaplastic lymphoma kinase (ALK) expression exists in approximately 60% of anaplastic large cell lymphoma (ALCL) cases.
  • Compared with the ALK-negative cases, ALK-positive cases are usually characterized by a good response to chemotherapy and a good prognosis.
  • In the relapsed or refractory ALCL cases, high-dose chemotherapy followed by autologous stem cell transplantation has been widely used as a salvage therapy.
  • However, 40% of patients who received transplants after more than 2 complete remissions eventually experienced disease progression, despite receiving autologous stem cell transplantation.
  • Allogeneic stem cell transplantation has been proposed as a therapeutic option in refractory ALCL cases, but clinical reports of adult patients are rare.
  • Herein, we report the case of an adult with refractory ALK-positive ALCL who was successfully treated with salvage high-dose chemotherapy followed by allogeneic stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321986.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1; CVAD protocol
  •  go-up   go-down


58. Kim YC, Yang WI, Lee MG, Kim SN, Cho KH, Lee SJ, Lee MW, Koh JK: Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea. Int J Dermatol; 2006 Nov;45(11):1312-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
  • AIM: To elucidate the possible association of EBV with CD30+ anaplastic large cell lymphoma (ALCL) involving the skin and lymphomatoid papulosis (LyP) in South Korea.
  • METHODS: In situ hybridization for EBV-encoded small RNA (EBER) and immunohistochemistry including viral latent membrane protein-1 (LMP-1) were performed on formalin-fixed, paraffin-embedded skin specimens of 26 cases of LyP and 16 cases of CD30+ ALCL involving the skin which were selected from six university hospital medical centers in South Korea.
  • RESULTS: In situ hybridization studies showed positivity of the neoplastic cells for EBER in two of 16 cases of CD30+ ALCL and in none of the cases of LyP.
  • One EBER-positive case was cutaneous CD30+ ALCL with concurrent lymph node involvement.
  • The other was CD30+ ALCL involving the skin and other organs, including lymph nodes, bone, lung, and spleen.
  • Immunostaining for LMP-1 was also positive only for the two cases of EBER-positive CD30+ ALCL.
  • CONCLUSION: LyP and primary cutaneous CD30+ ALCL are very rarely associated with EBV in South Korea.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / growth & development. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD30 / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Korea. Male. Middle Aged. RNA, Viral / genetics. Viral Matrix Proteins / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076712.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr virus encoded RNA 1; 0 / Epstein-Barr virus encoded RNA 2; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


59. Balwierz W, Czogała M, Czepko E: [Anaplastic large cell lymphoma associated with hemophagocytic lymphohistiocytosis: a case report and review of the literature]. Przegl Lek; 2010;67(6):436-8
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic large cell lymphoma associated with hemophagocytic lymphohistiocytosis: a case report and review of the literature].
  • Here we present a case report of a 14 years old boy diagnosed with HLH before recognition of anaplastic large cell lymphoma (ALCL).
  • Finally, histopathological examination of a subsequently excised enlarged lymph node demonstrated lesions typical for ALCL.
  • First-line therapy, according to protocol for this type of lymphoma, was introduced.
  • He was qualified for allogeneic stem cell transplantation.
  • Occurrence of HLH can cause diagnostic difficulties, because it often masks the underlying disease, especially when it is associated with infection.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Remission Induction. Stem Cell Transplantation


60. Braun FK, Hirsch B, Al-Yacoub N, Dürkop H, Assaf C, Kadin ME, Sterry W, Eberle J: Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol; 2010 Mar;130(3):826-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP.
  • We investigated death receptor-mediated apoptosis and CD30/CD95 crosstalk in four CD30-positive cell lines of cutaneous anaplastic large-cell lymphoma (cALCL).
  • Expression of TNF receptor 1 was lost in three of four cell lines, providing an explanation for TNF-alpha unresponsiveness.
  • TRAIL resistance may be explained by the consistent overexpression of cellular flice inhibitory protein (c-FLIP) (four of four cell lines) and frequent loss of the pro-apoptotic Bcl-2 protein Bid (three of four cell lines).
  • CD30/CD95 crosstalk experiments showed that CD30 ligation leads to NF-kappaB-mediated c-FLIP upregulation in cALCL cells, which in turn conferred enhanced resistance to CD95-mediated apoptosis.
  • Knockdown of c-FLIP by a lentiviral approach enhanced basic apoptosis rates in cALCL cells and diminished the CD30-mediated suppression of apoptosis, thus proving the significance of c-FLIP in this context.
  • Further clarifying the defects in apoptosis pathways in cutaneous lymphomas may lead to improved therapies for these disorders.
  • [MeSH-major] Antigens, CD30 / metabolism. Apoptosis / physiology. CASP8 and FADD-Like Apoptosis Regulating Protein / genetics. Lymphoma, Large-Cell, Anaplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD95 / metabolism. BH3 Interacting Domain Death Agonist Protein / metabolism. Caspases / metabolism. Cell Line, Tumor. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / physiology. Humans. NF-kappa B / metabolism. RNA Interference. Receptor Cross-Talk / physiology. Receptors, Tumor Necrosis Factor, Type I / metabolism. Up-Regulation / drug effects. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890350.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20RR018757
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD95; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / NF-kappa B; 0 / Receptors, Tumor Necrosis Factor, Type I; EC 3.4.22.- / Caspases
  •  go-up   go-down


61. Mori T, Takimoto T, Katano N, Kikuchi A, Tabuchi K, Kobayashi R, Ayukawa H, Kumagai MA, Horibe K, Tsurusawa M: Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol; 2006 Mar;132(5):594-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan.
  • This report presents a retrospective study of 26 Japanese children with recurrent anaplastic large cell lymphoma.
  • The first relapses were documented at a median of 10.5 months after the initial diagnosis.
  • The patients who received allogeneic haematopoietic stem cell transplantation during second CR showed a superior outcome to other patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Japan. Male. Neoplasm Recurrence, Local / mortality. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445832.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


62. Wan W, Albom MS, Lu L, Quail MR, Becknell NC, Weinberg LR, Reddy DR, Holskin BP, Angeles TS, Underiner TL, Meyer SL, Hudkins RL, Dorsey BD, Ator MA, Ruggeri BA, Cheng M: Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood; 2006 Feb 15;107(4):1617-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
  • The roles of aberrant expression of constitutively active ALK chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) have been well defined; nevertheless, the notion that ALK is a molecular target for the therapeutic modulation of ALK+ ALCL has not been validated thus far.
  • Select fused pyrrolocarbazole (FP)-derived small molecules with ALK inhibitory activity were used as pharmacologic tools to evaluate whether functional ALK is essential for the proliferation and survival of ALK+ ALCL cells in culture.
  • Inhibition of NPM-ALK phosphorylation in the ALK+ ALCL-derived cell lines resulted in significant inhibition of cell proliferation and induction of apoptotic-cell death, while having marginal effects on the proliferation and survival of K562, an ALK- leukemia cell line.
  • ALK inhibition resulted in cell-cycle G1 arrest and inactivation of ERK1/2, STAT3, and AKT signaling pathways.
  • Potent and selective ALK inhibitors may have therapeutic application for ALK+ ALCL and possibly other solid and hematologic tumors in which ALK activation is implicated in their pathogenesis.
  • [MeSH-major] Cell Division / physiology. Cell Survival / physiology. Lymphoma, Large B-Cell, Diffuse / enzymology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Apoptosis. Carbazoles / pharmacology. Caspases / metabolism. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Indazoles / pharmacology. Phenylurea Compounds / pharmacology. Receptor Protein-Tyrosine Kinases


63. Lamant L, de Reyniès A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S, Brugières L, Gaulard P, Espinos E, Delsol G: Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood; 2007 Mar 1;109(5):2156-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
  • With the use of microarray gene-expression profiling, we analyzed a homogeneous series of 32 patients with systemic anaplastic large-cell lymphoma (ALCL) and 5 ALCL cell lines.
  • Unsupervised analysis classified ALCL in 2 clusters, corresponding essentially to morphologic subgroups (ie, common type vs small cell and "mixed" variants) and clinical variables.
  • Patients with a morphologic variant of ALCL had advanced-stage disease.
  • Supervised analysis showed that ALK+ALCL and ALK- ALCL have different gene-expression profiles, further confirming that they are different entities.
  • Among the most significantly differentially expressed genes between ALK+ and ALK- samples, we found BCL6, PTPN12, CEBPB, and SERPINA1 genes to be overexpressed in ALK+ ALCL.
  • The molecular signature of ALK- ALCL included overexpression of CCR7, CNTFR, IL22, and IL21 genes but did not provide any obvious clues to the molecular mechanism underlying this tumor subtype.
  • Once confirmed on a larger number of patients, the results of the present study could be used for clinical and therapeutic management of patients at the time of diagnosis.
  • [MeSH-major] Cell Shape. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Cell Line, Tumor. Humans. Immunohistochemistry. RNA, Messenger / genetics. Receptor Protein-Tyrosine Kinases. Tissue Array Analysis


64. Damm-Welk C, Schieferstein J, Schwalm S, Reiter A, Woessmann W: Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction. Br J Haematol; 2007 Aug;138(4):459-66
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.
  • Quantification of occult circulating tumour cells in blood or bone marrow (BM) enables the identification of patients with a high risk for relapse in nucleophosmin/anaplastic lymphoma kinase (NPM-ALK)-positive anaplastic large cell lymphoma (ALCL).
  • We have developed a flow cytometric (FCM) assay to quantify the rare ALK- and CD30-positive ALCL cells.
  • When ALCL cells were admixed with normal peripheral blood or BM, ALK- and CD30-positive cells could be detected above background level at an added concentration of 10(-5) for all three cell lines tested.
  • Both methods were compared on BM or blood samples from 11 ALCL patients.
  • FCM using antibodies against ALK and CD30 can sensitively and specifically detect the circulating ALCL cells in BM or blood.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / analysis. Antigens, CD30 / immunology. Antigens, CD30 / metabolism. Bone Marrow Cells / chemistry. Costs and Cost Analysis. Flow Cytometry / economics. Flow Cytometry / methods. Humans. Nuclear Proteins / metabolism. Protein-Tyrosine Kinases / analysis. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / immunology. Protein-Tyrosine Kinases / metabolism. RNA, Messenger / analysis. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction / economics. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608768.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / Nuclear Proteins; 0 / RNA, Messenger; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


65. Tokura Y, Sugita K, Yagi H, Shimauchi T, Kabashima K, Takigawa M: Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S92-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion.
  • A 70-year-old Japanese male presented with a 1-year history of skin tumors, which were diagnosed as primary cutaneous anaplastic large cell lymphoma (ALCL) because of the CD3(low+), CD4(+), CD25(+), CD30(+), CD45RO(+), CD71(+), HLA-DR(+), CD8(-), CD56(-), and NPM/ALK(-) phenotype and monoclonal T-cell receptor-rearranged property of tumor cells as well as the absence of systemic involvement.
  • At this time, the tumor cell was positive for cutaneous lymphocyte-associated antigen (CLA) and TH(2) chemokine receptor CCR4.
  • The eruption had repeatedly appeared and spontaneously regressed or regressed by virtue of several therapeutic modalities, including radiotherapy, interferon-alpha and chemotherapy, until the tumor cell invaded the gastric mucosa and spread to the peripheral blood 5 years later.
  • Flow cytometric monitoring of the phenotype of peripheral blood and skin-infiltrating lymphocytes disclosed that the expression of CLA and CCR4 on the tumor cells was converted from positive to negative in association with the leukemic change.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Leukemia / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Receptors, Chemokine / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938033.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CCR4 protein, human; 0 / CTAGE1 protein, human; 0 / Membrane Glycoproteins; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


66. Chuang SS, Hsieh YC, Ye H, Hwang WS: Lymphohistiocytic anaplastic large cell lymphoma involving skin: a diagnostic challenge. Pathol Res Pract; 2009;205(4):283-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphohistiocytic anaplastic large cell lymphoma involving skin: a diagnostic challenge.
  • Systemic anaplastic large cell lymphoma (ALCL) involving the skin should be differentiated from primary cutaneous CD30-positive T-cell lymphoproliferative disorders.
  • The lymphohistiocytic variant of ALCL (LH-ALCL) is rich in reactive histiocytes with relatively few neoplastic cells, which pose a diagnostic challenge.
  • We present a case of LH-ALCL involving skin mimicking granulomatous inflammation.
  • Biopsy of the cervical lymph node showed LH-ALCL with null cell phenotype.
  • Microscopically, the cutaneous lesion was located predominately around the hair follicle, with numerous reactive histiocytes and scanty medium-sized lymphoma cells expressing CD30 and anaplastic lymphoma kinase (ALK) protein.
  • Furthermore, an ALK gene rearrangement was demonstrated by locus-specific interphase fluorescent in situ hybridization, confirming cutaneous involvement with LH-ALCL.
  • LH-ALCL involving the skin is a rare event, and the numerous reactive histiocytes may mask scanty tumor cells.
  • In addition to B-and T-cell markers, (dermato) pathologists must be aware of this entity in cutaneous lymphohistiocytic proliferations and perform immunostaining for CD30 and ALK to reach a correct diagnosis.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD30 / metabolism. Gene Rearrangement. Histiocytes / pathology. Humans. In Situ Hybridization, Fluorescence. Male. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091487.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


67. Engsig FN, Møller MB, Hasselbalch HK, Mahdi B, Obel N: Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage. APMIS; 2007 Jun;115(6):778-83
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage.
  • All microbiology tests and test for autoimmune disease were negative.
  • Conventional pathological examination of bone marrow and lymph node biopsies did not demonstrate malignant cells and inflammatory disease was suspected.
  • Immunohistochemistry and cytogenetics postmortem led to a diagnosis of anaplastic large cell lymphoma (ALCL) of T-cell lineage.
  • Involvement of peripheral blood with leukemoid reaction is a rare manifestation of ALCL.
  • [MeSH-major] Granulocytes / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neutrophils / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550390.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


68. Guerra J, Echevarria-Escudero M, Barrio N, Velez-Rosario R: Primary endobronchial anaplastic large cell lymphoma in a pediatric patient. P R Health Sci J; 2006 Jun;25(2):159-61
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endobronchial anaplastic large cell lymphoma in a pediatric patient.
  • A biopsy of the lesion demonstrated an anaplastic large cell lymphoma (ALCL).
  • Evaluation for disseminated disease was negative.
  • Although extranodal involvement of ALCL is frequent at some stage of the disease, endobronchial involvement is extremely rare even in the presence of advanced disease.
  • To our knowledge, this is the first primary isolated endobronchial ALCL described in a pediatric patient.
  • [MeSH-major] Bronchial Neoplasms. Lymphoma, Large B-Cell, Diffuse

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203715.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


69. Yamamoto H, Kohashi K, Oda Y, Tamiya S, Takahashi Y, Kinoshita Y, Ishizawa S, Kubota M, Tsuneyoshi M: Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene. Pathol Int; 2006 Oct;56(10):584-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene.
  • Some populations of IMT have anaplastic large cell lymphoma kinase (ALK) gene rearrangements.
  • Immunohistochemically, 15 cases were ALK positive and six were negative.
  • These results suggest that IMT may be a heterogeneous group in terms of pathogenesis, and EBV and HHV-8 do not play a major role in the pathogenesis of ALK-positive tumor.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984614.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / TPM3 protein, human; 0 / TPM4 protein, human; 0 / Tropomyosin; 0 / latency-associated nuclear antigen; 114899-12-6 / Clathrin Heavy Chains; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


70. van Kester MS, Tensen CP, Vermeer MH, Dijkman R, Mulder AA, Szuhai K, Willemze R, van Doorn R: Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol; 2010 Feb;130(2):563-75
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) has an indolent clinical course and favorable prognosis.
  • On the contrary, primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTL-NOS) shows aggressive clinical behavior.
  • To identify genomic events relevant in the pathogenesis of these cutaneous T-cell lymphomas (CTCLs), we carried out array-based comparative genomic hybridization (CGH) analysis.
  • C-ALCL was characterized by gains on chromosome 7q and 17q and losses on 6q and 13q.
  • We identified minimal common regions harboring candidate oncogenes and tumor suppressor genes in C-ALCL and PTL-NOS.
  • Genes with a role in lymphocyte chemotaxis, apoptosis, and proliferation were overrepresented among genes differentially expressed between these lymphomas.
  • C-ALCL showed higher expression of the skin-homing chemokine receptor genes CCR10 and CCR8, which may explain the lower tendency to disseminate to extracutaneous sites.
  • Furthermore, C-ALCL and PTL-NOS showed aberrant expression of distinct genes implicated in apoptosis and proliferation, such as IRF4/MUM1 and PRKCQ, which may account for differences in clinical aggressiveness.
  • [MeSH-major] Chromosome Aberrations. Gene Expression Regulation, Neoplastic. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / metabolism. Skin Neoplasms / genetics. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Chemokines / metabolism. Chromosome Mapping. Female. Genetic Predisposition to Disease. Humans. Lymphocytes / cytology. Male. Middle Aged


71. Min JA, Oh ST, Kim JE, Cho BK, Chung NG, Park HJ: Lymphomatoid papulosis followed by anaplastic large cell lymphoma in a pediatric patient. Ann Dermatol; 2010 Nov;22(4):447-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis followed by anaplastic large cell lymphoma in a pediatric patient.
  • Transformation to T-cell lymphoma has been well documented in 10% to 20% of adults with LyP.
  • Histological and immunohistochemical examination of the subcutaneous nodule revealed anaplastic large cell lymphoma (ALCL).
  • A T-cell receptor gene rearrangement analysis demonstrated an identical rearranged pattern in the two specimens, indicating that a common T-cell clone had proliferated over time in both the LyP and ALCL lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165218.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2991725
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Lymphomatoid papulosis
  •  go-up   go-down


72. Tamiolakis D, Papadopoulos N, Venizelos J, Kakagia D, Nikolaidou S, Bolioti S, Kouskoukis C: ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma. Onkologie; 2005 Jun;28(6-7):356-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma.
  • BACKGROUND: Anaplastic lymphoma kinase (ALK) expression has not been described in neutrophil-rich anaplastic large cell lymphoma (NR-ALCL).
  • CASE REPORT: A 12-year old female with a 4-weeks history of a non-resolving bump over the forehead resulting from injury, was diagnosed of stage IE cutaneous T-cell lymphoma, and radiation was employed.
  • Shortly after completion of therapy, there was progress of the disease on the soft tissue of the right hand, and bone marrow involvement was also found.
  • A fine-needle aspiration of the hand mass was performed, and a diagnosis of CD30+/ALK+ NR-ALCL, was rendered.
  • METHODS: We studied the morphological characteristics of CD30+/ALK+ NR-ALCL using histological methods.
  • A panel of antibodies were used to establish diagnosis and subtyping.
  • CONCLUSIONS: ALK-ALCL arising in the skin represents a single disease with a broad spectrum of morphology; clinicians and pathologists should be aware of this neutrophil-rich (NR) variant with aggressive clinical presentation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, Large B-Cell, Diffuse / pathology. Neutrophils / pathology. Protein-Tyrosine Kinases / blood. Skin Neoplasms / blood. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933425.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


73. Sohatee MA: A case of anaplastic large cell lymphoma: when you hear hoof beats, sometimes consider zebras, not horses. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic large cell lymphoma: when you hear hoof beats, sometimes consider zebras, not horses.
  • These investigations revealed the diagnosis to be anaplastic large cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2002 Sep;41(3A):127-50 [12405944.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):736-42 [10929023.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • (PMID = 21918660.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029356
  •  go-up   go-down


74. Gómez-Román JJ, Cobo ML, Val-Bernal JF: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int; 2008 Apr;58(4):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm.
  • Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration.
  • Reported herein is the case of a 45-year-old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK) and granzyme B positive) that presented as a bladder neoplasm.
  • The morphological differential diagnosis was complex because the EMA-positive immunophenotype, CD45 and CD3 negativity and the clinical manifestation simulated a transitional cell carcinoma.
  • It is important to be aware of its existence because a poorly differentiated bladder carcinoma cannot be ruled out if CD30 and ALK immunostaining are not performed.
  • T-cell receptor-gamma clonal rearrangement could be also helpful in these cases.
  • Although bladder involvement by recurrent lymphoma is a sign of widely disseminated disease and it is associated with a very poor prognosis, it seems that chemotherapeutic regimens in this kind of ALK-positive lymphoma could be effective, given that the present patient had an impressive response to chemotherapy treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Protein-Tyrosine Kinases / metabolism. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD30 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Etoposide / administration & dosage. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Mucin-1 / metabolism. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324919.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / Mucin-1; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


75. Chao-Lo MP, King-Ismael D, Lopez RA: Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep; 2008 Oct 11;2(3):31-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case.
  • Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare type of non-Hodgkin's lymphoma comprising approximately 0.9-9.0% of all cutaneous lymphomas.
  • PCALCL is characterized by the absence of systemic involvement, spontaneous regression and low recurrence rate especially in localized lesions.We present a 47-year-old female with a 1½-year history of two asymptomatic erythematous indurated plaques on the right arm.
  • Skin punch biopsy revealed dense infiltrates of non-epidermotropic, large, irregularly-shaped lymphocytes with hyperchromatic and pyknotic nuclei.
  • Immunohistochemistry revealed that these atypical cells are anaplastic lymphoma kinase (ALK) positive, CD30+, CD3-, CD20- and epithelial membrane antigen (EMA) negative.
  • Work-ups revealed no systemic involvement.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 2):857-61 [10321635.001]
  • [Cites] Eur J Pediatr. 2008 Jan;167(1):111-3 [17219127.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):793-6 [11050582.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):142-7 [12652196.001]
  • [Cites] J Am Acad Dermatol. 2003 Dec;49(6):1049-58 [14639383.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2004 May-Jun;70(3):168-71 [17642599.001]
  • [Cites] Blood. 2007 Jul 15;110(2):479-84 [17339420.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1319-32, vii-viii [14710887.001]
  • [Cites] Pediatr Dermatol. 2004 May-Jun;21(3):212-7 [15165197.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1202-7 [15214912.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1):103-10 [15243534.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):221-6 [16104878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:323-30, 513 [17124079.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):422-8 [11048978.001]
  • (PMID = 21886709.001).
  • [ISSN] 1898-7249
  • [Journal-full-title] Journal of dermatological case reports
  • [ISO-abbreviation] J Dermatol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3157779
  • [Keywords] NOTNLM ; lymphomatoid papulosis / lymphoproliferative disorders / mycosis fungoides / primary cutaneous CD30 positive large T cell lymphoma / primary cutaneous anaplastic large cell lymphoma
  •  go-up   go-down


81. Liao WP, Dai MS, Hsu LF, Yao NS: Anaplastic large-cell lymphoma primarily infiltrating femoral muscles. Ann Hematol; 2005 Oct;84(11):764-6
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell lymphoma primarily infiltrating femoral muscles.
  • [MeSH-major] Carcinoma, Large Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Muscle, Skeletal / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Biopsy. Femur. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086180.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


82. Dalal BI, Chhanabhai M, Horsman DE, LeHuquet J, Coupland R: Anaplastic large-cell lymphoma presenting as acute leukemia. Am J Hematol; 2005 Jun;79(2):164-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell lymphoma presenting as acute leukemia.
  • [MeSH-major] Leukemia / etiology. Leukemia / pathology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged. Neoplastic Cells, Circulating / pathology


83. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, we recently reported an evidence based review of guidelines for the P and T of TLS (Coiffier et al, J Clin Oncol. 2008).
  • 2001) and a rapid reduction in UA in adults at high-risk of TLS (Coiffier et al, J Clin Oncol. 2003).
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.
  • CONCLUSIONS: This medical decision tree will facilitate the practice of management of the P and T of TLS and hopefully improve the quality of care in a cost effective manner.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Kwak EL, Camidge DR, Clark J, Shapiro GI, Maki RG, Ratain MJ, Solomon B, Bang Y, Ou S, Salgia R: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol; 2009 May 20;27(15_suppl):3509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types included colorectal, pancreatic, sarcoma, ALCL and NSCLC.
  • Among 10 NSCLC pts whose tumors harbor EML4-ALK rearrangement, 1 pt has had a PR, 2 pts have achieved unconfirmed PR and 4 pts have had SD (3 have experienced reduction in tumor burden by ∼20% in measurable lesions and 1 has been treated for 28 weeks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961297.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Borchmann P: CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis. Cancer Treat Res; 2008;142:349-65
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large-Cell, Anaplastic. Lymphomatoid Papulosis. Skin Neoplasms


86. Sugaya M, Murai T, Tamaki K: Anaplastic large cell lymphoma associated with parapsoriasis en plaques. Acta Derm Venereol; 2008;88(3):308-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma associated with parapsoriasis en plaques.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Parapsoriasis / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology


87. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD, International Peripheral T-Cell Lymphoma Project: ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood; 2008 Jun 15;111(12):5496-504
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
  • The International Peripheral T-Cell Lymphoma Project is a collaborative effort designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell lymphomas (PTCLs).
  • Of the 1314 eligible patients, 181 had anaplastic large-cell lymphoma (ALCL; 13.8%) on consensus review: One hundred fifty-nine had systemic ALCL (12.1%) and 22 had primary cutaneous ALCL (1.7%).
  • Patients with anaplastic lymphoma kinase-positive (ALK(+)) ALCL had a superior outcome compared with those with ALK(-) ALCL (5-year failure-free survival [FFS], 60% vs 36%; P = .015; 5-year overall survival [OS], 70% vs 49%; P = .016).
  • However, contrary to prior reports, the 5-year FFS (36% vs 20%; P = .012) and OS (49% vs 32%; P = .032) were superior for ALK(-) ALCL compared with PTCL, not otherwise specified (PTCL-NOS).
  • Patients with primary cutaneous ALCL had a very favorable 5-year OS (90%), but with a propensity to relapse (5-year FFS, 55%).
  • In summary, ALK(-) ALCL should continue to be separated from both ALK(+) ALCL and PTCL-NOS.
  • Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed.
  • Primary cutaneous ALCL is associated with an indolent course.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / mortality. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell, Peripheral / mortality. Lymphoma, T-Cell, Peripheral / pathology. Protein-Tyrosine Kinases / immunology
  • [MeSH-minor] Adult. Asia. Diagnosis, Differential. Europe. Female. Follow-Up Studies. Humans. Immunophenotyping. International Cooperation. Male. Middle Aged. North America. Prognosis. Receptor Protein-Tyrosine Kinases. Recurrence. Retrospective Studies. Skin Neoplasms / immunology. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18385450.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Investigator] Savage K; Connors J; Gascoyne R; Chhanabhai M; Wilson W; Jaffe E; Armitage J; Vose J; Weisenburger D; Anderson J; Ullrich F; Bast M; Hochberg E; Harris N; Levine A; Nathwani B; Miller T; Rimsza L; Montserrat E; Lopez-Guillermo A; Campo E; Cuadros M; Alvarez Ferreira J; Martinez Delgado B; Holte H; Delabie J; Rüdiger T; Müller-Hermelink K; Reimer P; Adam P; Wilhelm M; Schmitz N; Nerl C; Lister A; Norton A; MacLennan KA; Zinzani PL; Pileri S; Federico M; Bellei M; Coiffier B; Berger F; Tanin I; Wannakrairot P; Au W; Liang R; Loong F; Rajan S; Sng I; Tobinai K; Matsuno Y; Morishima Y; Nakamura S; Seto M; Tanimoto M; Yoshino T; Suzumiya J; Ohshima K; Kim WS; Ko YH
  •  go-up   go-down


88. Siebert S, Amos N, Williams BD, Lawson TM: Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome. Semin Arthritis Rheum; 2007 Aug;37(1):63-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome.
  • Our aim was to describe a case of primary hepatic anaplastic large-cell lymphoma (ALCL) presenting as a rheumatic syndrome.
  • METHODS: A patient with ALCL presenting with arthralgia and systemic inflammation is described.
  • He ultimately underwent partial hepatectomy for an enlarging liver lesion, which was demonstrated to be primary hepatic ALCL on immunohistochemistry.
  • There are a few reports of ALCL presenting as bone lesions, but to our knowledge this is the first report of hepatic ALCL presenting with a rheumatic syndrome.
  • The tumor produced large quantities of the proinflammatory cytokines interleukin-6 (IL-6) and IL-8 but did not produce tumor necrosis factor-alpha (TNF-alpha), IL-1, or IL-4.
  • The ALCL tissue in our patient produced large quantities of the IL-6, which we believe was associated with the patient's systemic inflammation.
  • [MeSH-major] Interleukin-6 / metabolism. Liver Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Rheumatic Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Middle Aged


89. Jarzembowski JA: Anaplastic large cell lymphoma: looks can be deceiving. Pediatr Dev Pathol; 2007 May-Jun;10(3):169-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma: looks can be deceiving.
  • [MeSH-major] Biomarkers, Tumor / immunology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Dev Pathol. 2007 May-Jun;10(3):181-91 [17535098.001]
  • (PMID = 17535094.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Shiohara J, Koga H, Uhara H, Takata M, Saida T, Uehara T: Herpes zoster histopathologically mimicking CD30-positive anaplastic large cell lymphoma. J Eur Acad Dermatol Venereol; 2009 May;23(5):618-9
MedlinePlus Health Information. consumer health - Shingles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes zoster histopathologically mimicking CD30-positive anaplastic large cell lymphoma.
  • [MeSH-major] Antigens, CD30 / analysis. Herpes Zoster / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759786.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


91. Watanabe N, Kato H, Murakami J, Shimizu M, Noguchi K, Kamisaki Y, Matsunari I, Seto H: FDG-PET imaging in cutaneous anaplastic large cell lymphoma. Clin Nucl Med; 2006 Sep;31(9):564-5
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET imaging in cutaneous anaplastic large cell lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921287.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Park SJ, Kim S, Lee DH, Jeong YP, Bae Y, Han EM, Huh J, Suh C: Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center. Yonsei Med J; 2008 Aug 30;49(4):601-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center.
  • PURPOSE: Anaplastic large cell lymphoma (ALCL), a CD30+ T-cell non-Hodgkin's lymphoma, represents only 2-8% of lymphoma overall.
  • Information on the clinical findings of primary systemic ALCL in Korea is limited.
  • Our aims were to report the clinical features and outcomes of primary systemic ALCL.
  • PATIENTS AND METHODS: We retrospectively reviewed the medical records of 36 adult patients diagnosed with primary systemic ALCL at Asan Medical Center from February 1995 through June 2006.
  • Univariate analysis showed that performance status (p = 0.035), international prognostic index (IPI) (p = 0.025), and age-adjusted IPI (p = 0.034) were significant prognostic factors for OS, whereas anaplastic lymphoma kinase (ALK) expression did not affect OS (p = 0.483).
  • CONCLUSION: Our retrospective analysis of Korean primary systemic ALCL patients showed that median OS was 49 months and overall response to CHOP was 91%.
  • [MeSH-major] Hospitals. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):633-8 [16891805.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):172-8 [11391714.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] Hematol Oncol. 2001 Dec;19(4):129-50 [11754390.001]
  • [Cites] J Pathol. 2003 May;200(1):4-15 [12692835.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1727-31 [14692525.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Br J Haematol. 1990 Feb;74(2):161-8 [2156548.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):943-9 [7683712.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1995 Jan 1;85(1):1-14 [7803786.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):955-62 [8622045.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):319-27 [8819081.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3727-34 [9345059.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Haematologica. 1999 May;84(5):425-30 [10329921.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Histopathology. 2006 Apr;48(5):481-504 [16623775.001]
  • [Cites] Hematol Oncol. 1999 Dec;17(4):137-48 [10725869.001]
  • (PMID = 18729302.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2615286
  •  go-up   go-down


93. El-Osta HE, Salyers WJ Jr, Palko W, Hagan ME, El-Haddad B, Schulz TK: Anaplastic large-cell lymphoma with leukemoid reaction. J Clin Oncol; 2008 Sep 10;26(26):4356-8
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell lymphoma with leukemoid reaction.
  • [MeSH-major] Leukemoid Reaction / immunology. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779625.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Nassiri M, Byrne GE, Whitcomb CC, Byrnes JJ: Synchronous null-cell anaplastic large cell lymphoma and multiple myeloma. Ann Hematol; 2009 Sep;88(9):923-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous null-cell anaplastic large cell lymphoma and multiple myeloma.
  • [MeSH-major] Lymphocytes, Null / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Multiple Myeloma / pathology. Skin / pathology


95. Hegde R: Radiotherapy in cutaneous anaplastic large cell lymphoma. J Cutan Aesthet Surg; 2010 Jan;3(1):52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy in cutaneous anaplastic large cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 2009 Jun;145(6):667-74 [19528422.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1095-1107 [14696593.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1542-5 [18037577.001]
  • (PMID = 20606998.001).
  • [ISSN] 0974-5157
  • [Journal-full-title] Journal of cutaneous and aesthetic surgery
  • [ISO-abbreviation] J Cutan Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2890140
  •  go-up   go-down


96. Bakshi NA, Ross CW, Finn WG, Valdez R, Ruiz R, Koujok K, Schnitzer B: ALK-positive anaplastic large cell lymphoma with primary bone involvement in children. Am J Clin Pathol; 2006 Jan;125(1):57-63
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive anaplastic large cell lymphoma with primary bone involvement in children.
  • We describe the clinical, radiologic, and pathologic features of primary bone anaplastic large cell lymphoma (ALCL) in 3 boys.
  • Bone was the only site of disease in 2 cases; an associated partial lymph node was involved in case 3.
  • Differential diagnoses included osteomyelitis and small round cell tumors of childhood, particularly Ewing sarcoma.
  • Preoperatively, ALCL was not a diagnostic consideration in any case.
  • Two cases showed classic large pleomorphic cells; 1 showed a composite pattern with a distinct small cell component and the more typical large cell type.
  • Neoplastic cells in all cases showed strong CD30 and anaplastic lymphoma kinase expression with relatively weak epithelial membrane antigen positivity.
  • Two patients were disease-free at last follow-up (15 months and 11 years); 1 patient died of disseminated disease within a year of diagnosis.
  • ALCL should be considered a diagnostic possibility when evaluating neoplastic bone lesions in children.
  • Although expression of NSE in ALCL has not been emphasized in the literature, it is worth noting because it may pose a diagnostic pitfall.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482992.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


97. Burnham JM, Kreiger PA, Paessler M, Kersun LS, Cron RQ: Picture of the month: anaplastic large cell lymphoma with hemophagocytic lymphohistiocytosis. Arch Pediatr Adolesc Med; 2006 Nov;160(11):1177-9
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Picture of the month: anaplastic large cell lymphoma with hemophagocytic lymphohistiocytosis.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, Large-Cell, Anaplastic / pathology


98. Moreno L, Garzón L, Bautista FJ, Fernández Navarro JM, András MM, Verdeguer A: Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution. Clin Transl Oncol; 2009 May;11(5):318-21
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution.
  • INTRODUCTION: Anaplastic large-cell lymphoma (ALCL) is an infrequent childhood malignancy whose diagnosis and treatment have largely evolved since its initial description in 1985.
  • RESULTS: Our first patient was diagnosed shortly alter this entity was described based on morphology and Ki-1 positivity, while the diagnostic work-up for the last two children included accurate molecular diagnosis for ALK-NPM rearrangement.
  • After 156 months of median follow-up (range 4-245), 8 out of 9 children are alive, free of disease.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / drug therapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451065.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L: Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A; 2010 Sep 14;107(37):16228-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
  • Aberrant anaplastic lymphoma kinase (ALK) expression is a defining feature of many human cancers and was identified first in anaplastic large-cell lymphoma (ALCL), an aggressive non-Hodgkin T-cell lymphoma.
  • We have identified a distinct profile of micro-RNAs (miRNAs) that characterize ALCL; furthermore, this profile distinguishes ALK(+) from ALK(-) subtypes, and thus points toward potential mechanisms of tumorigenesis induced by aberrant ALK.
  • Using a nucleophosmin-ALK transgenic mouse model as well as human primary ALCL tumor tissues and human ALCL-derived cell lines, we reveal a set of overlapping deregulated miRNAs that might be implicated in the development and progression of ALCL.
  • Importantly, ALK(+) and ALK(-) ALCL could be distinguished by a distinct profile of "oncomirs": Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL.
  • Moreover, miR-101 was down-regulated in all ALCL model systems, but its forced expression attenuated cell proliferation only in ALK(+) and not in ALK(-) cell lines, perhaps suggesting different modes of ALK-dependent regulation of its target proteins.
  • Furthermore, inhibition of mTOR, which is targeted by miR-101, led to reduced tumor growth in engrafted ALCL mouse models.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / enzymology. Lymphoma, Large-Cell, Anaplastic / genetics. MicroRNAs / genetics. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Base Sequence. Cell Line, Tumor. Cell Proliferation. Gene Expression Profiling. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Mice. Mice, Transgenic. Multigene Family. Receptor Protein-Tyrosine Kinases. Sirolimus / analogs & derivatives. Sirolimus / therapeutic use. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Blood. 1988 Sep;72(3):1045-7 [3416066.001]
  • [Cites] Br J Haematol. 1990 Feb;74(2):161-8 [2156548.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] FASEB J. 1997 Oct;11(12):965-72 [9337149.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2901-10 [9376569.001]
  • [Cites] Nat Med. 2005 Jun;11(6):623-9 [15895073.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1131-3 [16082218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6589-97 [16818631.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3275-9 [17094440.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1621-30 [17416736.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3374-83 [17690253.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Cell. 2008 Apr 18;133(2):217-22 [18423194.001]
  • [Cites] J Virol. 2008 Sep;82(18):9065-74 [18596100.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1135-42 [19155302.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2623-9 [19258506.001]
  • [Cites] Circ Res. 2009 May 22;104(10):1184-91 [19390056.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1005-17 [19524505.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1585-95 [19531656.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4232-5 [19667260.001]
  • [Cites] Mol Cancer Res. 2009 Sep;7(9):1466-76 [19737969.001]
  • [Cites] Leukemia. 2009 Nov;23(11):2129-38 [19657361.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1583-90 [20159827.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2309-10 [12057933.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):875-83 [12213716.001]
  • [Cites] Oncogene. 2003 Jan 30;22(4):517-27 [12555065.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1919-27 [12424201.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7750-61 [14586401.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] J Immunol. 1980 Feb;124(2):879-84 [7188701.001]
  • [Cites] Blood. 1988 Jul;72(1):234-40 [3260522.001]
  • [Cites] Blood. 2010 May 27;115(21):4191-7 [20089965.001]
  • (PMID = 20805506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / V 102
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / MicroRNAs; 624KN6GM2T / temsirolimus; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2941277
  •  go-up   go-down


100. Davis AK, Cole-Sinclair M, Russell P: Anaplastic large cell lymphoma presenting with paraneoplastic pemphigus. J Clin Pathol; 2007 Jan;60(1):108-10
MedlinePlus Health Information. consumer health - Pemphigus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma presenting with paraneoplastic pemphigus.
  • [MeSH-major] Autoimmune Diseases / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Paraneoplastic Syndromes / etiology. Pemphigus / etiology






Advertisement